60th ERA Congress
Milan & Virtual
June 15-18, 2023

Amazing Nephrology

Final Programme

ERA 60
Leading European Nephrology
Anniversary
CONGRESS INFORMATION

Please click on the links below to see the content.

> GENERAL INFORMATION
> ERA COUNCIL MEMBERS
> CONGRESS SCIENTIFIC COMMITTEE
> BEST ABSTRACTS
  ★ Ten best abstracts
  ☀ Eight best abstracts presented by young authors
  ❤ Best abstracts presented by young authors
Dear colleagues and friends,
As many of you may remember, the 2020 Congress was supposed to be held in Milan (Italy), but due to the difficulties and the lockdown caused by Covid 19, we were forced to hold the Congress virtually.
Now, after three years, we are very happy to be able to welcome all of you face-to-face in Milan.
The ERA Annual Congress aims at sharing knowledge to further improve the prevention and quality of life of patients by providing an update on the clinical assessment and treatment of kidney diseases.
This year’s theme, Research, Education, Governance and Equality, was chosen by Francesca Mallamaci, Chair of the Scientific Committee.

Research: is the basis of our lives, new therapies and the confirmation of old ones will not only support the cure of kidney disease but will also improve the quality of life of kidney patients.

Education: we are looking into the future. Healthcare professionals want to be prepared to provide high-quality, evidence-based care, adapt to new technologies and contribute to ongoing advances in medical practice and research.

Governance and equity are two interrelated concepts that play a crucial role in shaping societies and ensuring fair and equitable systems. Health equity focuses on ensuring that everyone has equal access to health services and that health outcomes are not determined by factors such as gender, race, income, or social status. It includes addressing health disparities and promoting health equity.

As in the past, the first day of the Milan 2023 Congress will feature educational sessions organised by the CME (Continuing Medical Education) Committee, chaired by Marianne Verhaar, as well as hands-on courses, overseen by Kate Stevens. This year, the CME Committee has planned four hands-on courses and eight CME courses lasting from half a day to a full day. The Scientific Committee, chaired by Francesca Mallamaci, worked very hard to provide the best programme by selecting international experts and well-known KoLs (Key opinion Leaders). She was in particular supported by Ronald Gansevoort, who chaired the paper selection committee, and by the Congress President, Piergiorgio Messa, and the Honorary Congress President, Loreto Gesualdo.

A large number of high-quality abstracts, received from 86 countries, confirms the strong interest in our Congress, furthermore, we received a record number of Late Breaking Clinical Trial (LBCT) abstracts that resulted in presenting two sessions of LBCT, for a total of eight large randomised clinical trials, clearly indicating that clinical research in kidney disease is growing.

A novelty introduced from the 60th ERA Congress is the simplification and harmonization of the number and content of Congress tracks and abstract categories, from 18 main categories and 38 subcategories to 7 main categories (the same as the Congress themes), we will also have two new sessions on clinical practice.
The programme will also include a new session to replace the standard Poster session: the Focussed Orals. All accepted abstracts will be discussed orally in dedicated rooms located within the exhibition area. No more paper posters for a more sustainable congress and more space for discussion.
An additional and new educational opportunity that you can take advantage of are the Creative Labs, a frontal lesson that will give you in-depth knowledge into specific practical topics. Experts will give you important and up-to-date information on the checklist for setting up a clinical trial, ethics in publishing, how to ruin your presentation and balancing parenthood and career.

Finally, the programme will be completed with several interesting industry symposia.
The Milan 2023 Congress will also be an opportunity to celebrate how much history and dedication have shaped our Association in its 60-year commitment to reducing the burden of chronic kidney disease. It’s great to be celebrating such a milestone and we hope that the Congress will be a successful and enlightening event for all those who attend.

We look forward to welcoming you to the 60th ERA Congress!
# CONTENT & DAILY INDEX

## SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday - June 15, 2023</td>
<td>5</td>
</tr>
<tr>
<td>Friday - June 16, 2023</td>
<td>11</td>
</tr>
<tr>
<td>Saturday - June 17, 2023</td>
<td>26</td>
</tr>
<tr>
<td>Sunday - June 18, 2023</td>
<td>42</td>
</tr>
</tbody>
</table>

## MODERATED ORALS & FOCUSED ORALS

<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday - June 16, 2023</td>
<td>25</td>
</tr>
</tbody>
</table>

## INDUSTRY SPONSORED SYMPOSIA

<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday - June 16, 2023</td>
<td>46</td>
</tr>
<tr>
<td>Saturday - June 17, 2023</td>
<td>56</td>
</tr>
</tbody>
</table>
CME & HANDS-ON COURSES

CONGRESS OPENING 6
PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES 6
HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD 6
CKD AND BONE MINERAL DISORDERS IN CKD 6
KIDNEY TRANSPLANTATION 7
HAND-ON COURSE ON RENAL BIOPSY (MORNING COURSE) 7
HAND-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA (FULL DAY) 7
HAND-ON COURSE ON CATHETER PLACEMENT (MORNING COURSE) 7
HAND-ON COURSE ON POCUS (FULL DAY COURSE) 8
HAEMO- AND PERITONEAL DIALYSIS 8
BASICS OF GENETICS FOR NEPHROLOGISTS 8
ACUTE KIDNEY INJURY 8
ELECTROLYTES AND UROLITHIASIS 9
HAND-ON COURSE ON RENAL BIOPSY (AFTERNOON COURSE) 9
HAND-ON COURSE ON CATHETER PLACEMENT (AFTERNOON COURSE) 9
WELCOME CEREMONY + WELCOME LECTURE 10
CONGRESS OPENING
Welcome words
Piergiorgio Messa (Local Congress President), Italy

Abstract submission
Ronald Gansevoort (Chair of Paper Selection Committee), The Netherlands

Most important sessions
Francesca Mallamaci (Chair of Scientific Committee), Italy

Congress official opening
Christoph Wanner (ERA President), Germany

CME 1
PRIMARY & SECONDARY GN, VASCULITIS AND AUTOIMMUNE DISEASES
Chairs: Annette Bruchfeld, Andreas Kronbichler

1. Predicting kidney function recovery in ANCA-associated vasculitis and anti-GBM disease
   Alan Salama, United Kingdom

2. Deposition diseases and the kidney – diagnostic steps beyond the kidney and therapeutic aspects
   Helen Lachmann, United Kingdom

3. B-cell depletion in podocytopenopathies and membranous nephropathy
   Philipp Gaukler, Austria

4. Pathology in lupus nephritis – 2023 revised
   Maddalena Maria Bolognesi, Italy

5. ANCA-associated vasculitis in the elderly – diagnostic and therapeutic aspects.
   Maria Weiner, Sweden

CME 2
HYPERTENSION, DIABETES, CARDIOVASCULAR DISEASES IN CKD
Chairs: Beatriz Fernandez Fernandez, Pantelis Sarafidis, Amaryllis Van Craenenbroeck

PART 1: REVISITING THE ROLE OF NATRIURESIS/DIURESIS IN CKD

1. Mechanisms on diuretic resistance in CKD
   Amaryllis Van Craenenbroeck, The Netherlands

2. Renal mechanisms involved in the benefits offered by SGLT2 inhibitors in HF
   Maria Eleni Alexandrou, Greece

3. BP CONTROL with diuretic treatments. Old drugs back into business
   Beatriz Fernández-Fernández, Spain

4. Is there a still a role for diuretics in hemodialysis and peritoneal dialysis?
   Manfred Hecking, Austria

5. Round table discussion

PART 2: NOVEL DIAGNOSTIC ASPECTS IN CKD

1. Bold MRI to assess tubulointerstitial damage in CKD
   Menno Prujim, Switzerland

2. Blood pressure control and cardiovascular risk factors in the COVID 19 era
   Andrzej Januszewicz, Poland

3. Discussion

PART 3: NOVEL THERAPEUTIC ASPECTS IN CKD

4. Cardiovascular morbidity and mortality reduction in CKD. Do SGLT2 inhibitors and finerenone finally change the landscape?
   Charles Ferro, United Kingdom

   Lucia del Vecchio, Italy

CME 3
CKD AND BONE MINERAL DISORDERS IN CKD
Chairs: Hanne Joergensen, Jelmer Humalda, Sandra Mazzaferrro

1. Introduction: Treatment targets in CKD-MBD
   Hanne Jørgensen, Denmark

2. Pathophysiology of hyperparathyroidism in bone and vessels
   Lucile Figueres, France

3. Response to PTH in target organs
   Pieter Evenepoel, Belgium

4. PTH; standardizing assays and killing myths
   Etienne Cavalier, Belgium

5. Quiz: How would you handle this case in clinical practice?
   Jelmer Humalda, The Netherlands

6. Expert panel: How would you handle this case in clinical practice?
   Lucile Figueres, France
   Pieter Evenepoel, Belgium
   Matthias Haarhaus, Sweden

7. Calcium balance – a forgotten target in CKD?
   Rukshana Shroff, United Kingdom

8. Bone and vascular biomarkers as treatment targets of CKD-MBD
   Maria Fusaro, Italy

9. Future aspects in CKD-MBD treatment targets
   Sandra Mazzaferrro, Italy
15 THU

SCIENTIFIC PROGRAMME

CME 5

KIDNEY TRANSPLANTATION

Chairs: Marta Crespo, Christophe Mariat, Jasper Callemeyn
1. Allerecognition and the spectrum of kidney transplant rejection
   Jasper Callemeyn, Belgium
2. PRO/CON topic: Do I treat subclinical ABMR? In response to a clinical case
   (Pro Speaker) O. Thaunat, France
   (Con Speaker) Georg Böhmeig, Austria
3. Xenotransplantation: the ultimate solution for end-stage renal disease?
   Manuel Pascual, France
4. Therapeutic strategies to improve allograft longevity: new drugs for diabetes
   Isabel Perez-Flores, Spain
5. Safety of immune checkpoint inhibitor therapy after kidney transplantation
   Ben Sprangers, Belgium

HAND-ON COURSE ON RENAL BIOPSY (MORNING COURSE)

This course will be done using MAX-CORE biopsy systems; please consider that similar products from other companies are available on the market

Chairs: Emily McQuarrie, Loreto Gesualdo
1. Introduction
   Emily McQuarrie, United Kingdom
2. Indications and epidemiology of native kidney biopsy
   Colin Geddes, United Kingdom
3. Practical aspect of Biopsy
4. Practical pathology for Biopsy (Processing of the samples and tests)
   Candice Roufosse, United Kingdom
5. Complications of Kidney Biopsy
   Loreto Gesualdo, Italy
6. US demonstration
   Antonio Granata, Italy
7. Biopsy demonstration and Practice
   Emily McQuarrie, United Kingdom
   Loreto Gesualdo, Italy
   Stefanie Heidenreich, Germany
   Adele Mitrotti, Italy
   Michele Rossini, Italy
   Mauro Forcella, Italy
   Antonio Granata, Italy
   Eleni Ioannou, Greece
   Keith Gillis, United Kingdom

HAND-ON COURSE ON ULTRASOUND OF ARTERIOVENOUS FISTULA (FULL DAY)

Chairs: Tamara Jemcov, José Ibeas
1. Introduction
   José Ibeas, Spain
2. How to examine a vascular access
   Jernej Pajek, Slovenia
3. Non maturing AVF
   Tamara Jemcov, Serbia
4. Venous outflow Stenosis
   Nicola Pirazzi, Italy
5. The aneurysmal AVF
   Karen Stevenson, United Kingdom
6. Discussion
7. Graft thrombosis
   Karen Stevenson, United Kingdom
8. Recirculation
   Matteo Tozzi, Italy
9. US demonstration
   Jose Ibeas, Spain
10. US practice
    Jose Ibeas, Spain
    Jennifer Hanko, United Kingdom
    Tamara Jemcov, Serbia
    Mariusz Kusztal, Poland
    Jernej Pajek, Slovenia
    Nicola Pirazzi, Italy
    Karen Stevenson, United Kingdom
    Matteo Tozzi, Italy
11. Concluding Remarks
    Jose Ibeas, Spain

HAND-ON COURSE ON CATHETER PLACEMENT (MORNING COURSE)

This course will be done using Palindrome™ catheter family; please consider that similar products from other companies are available on the market

Chairs: Kate Stevens, Maurizio Gallieni
1. Introduction
   Kate Stevens, United Kingdom
2. Minimising catheter associated infection
   Maria Guedes Marques, Portugal
3. Kinking and Tip position
   Carlo Lomonte, Italy
4. Assessment and management of central vein stenosis and atrial thrombus
   Sokratis Stoumpos, United Kingdom
5. Discussion
6. Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion
   Maurizio Gallieni, Italy
7. Practice
   Kate Stevens, United Kingdom
   Maurizio Gallieni, Italy
   Maria Guedes Marques, Portugal
   Jennifer Lees, United Kingdom
   Carlo Lomonte, Italy
   Sokratis Stoumpos, United Kingdom
   Peter Thomson, United Kingdom
   Paolo Ria, Italy
   Paolo Luca Maria, Italy
   Ioannis Giannikouri, Greece

The 2023 Hands-on courses will be done using the following ultrasound devices: SonoEye P2, Resona 19 and M9, CERBERO 4.0, Ultrasound System 3300 and CX50. Please consider that similar products from other companies are available on the market.
HAND-ON COURSE ON POCUS (FULL DAY COURSE)

Chairs: Hugo Diniz & Gregorio Gonzalez

1. Introduction
Hugo Diniz, Portugal

2. POCUS in Nephrology: what's the point?
Hugo Diniz, Portugal

3. Discussion

José Mariz, Portugal

5. POCUS of the kidney and urinary tract
Sinead Stoneman, Ireland

6. Discussion

7. Lung and cardiac US for the nephrologist
Fredzio Amada Graterol Torres, Spain

8. POCUS for volemia assessment: wet or dry?
Gregorio Gonzalez, Spain

9. Discussion

Clinical case discussion
Filipa Ferreira, Portugal
Raquel Barba, Spain

10. POCUS practice
Hugo Diniz, Portugal
Sinead Stoneman, Ireland
Raquel Barba, Spain
Filipa Ferreira, Portugal
Fredzio Amada Graterol Torres, Spain
Carlos Norváez Mejía, Spain
José Mariz, Portugal
James Gleeson, Ireland
Gregorio A. Romero-Gonzalez, Spain
Marco Antonio Vaca Gallardo, Spain

11. Concluding remarks
Hugo Diniz, Portugal

CME 4
HAEMO- AND PERITONEAL DIALYSIS

Chairs: Rukshana Shroff, Mehmet Kanbay, Karlien Francois

SESSION I – Volume management
Chairs: Carlo Basile and Rukshana Shroff

1. Hemodynamic instability in patients on dialysis: causes and management
Mehmet Kanbay, Turkey

2. Dialysis vs medications for heart failure? - a cardiologist's perspective
Frederik Verbrugge, Belgium

3. Optimizing dialysis for patients with heart failure
Andrew Davenport, United Kingdom

4. Round table discussion

SESSION II – Best practice in dialysis
Chairs: Sandip Mitra and Karlien Francois

1. Transition between kidney replacement therapies
Christian Combe, France

2. Care for elderly dialysis patients
Marjolijn van Buren, The Netherlands

3. Point of care ultrasound in nephrology
Joaquin Escola, Spain

4. Round table discussion

SESSION III – Dialysis Access in 2023
Chairs: Mehmet Kanbay and Gaetano Alfano

1. The complex relationship among arteriovenous access, heart, and circulation.
Carlo Basile, Italy

2. Best practice in AVF cannulation
Giacomo Forneris, Italy

3. Improving PD access - learning from registry data
Martin Wilkie, United Kingdom

4. Round table discussion

CME 8
BASICS OF GENETICS FOR NEPHROLOGISTS

Chairs: Emilie Cornec-Le Gall, Roser Torra, Lucille Figueres

1. Test your knowledge in basics of genetics: Let’s start by a quizz session
Elisabet Ars, Spain

2. Actionable genes in kidney diseases: definition and practical examples
Jan Hallbritter, Germany

Djalila Meckali, Belgium

4. Genetics for the transplant nephrologist
Peter Conlon, Ireland

5. Genetic-based therapeutic approaches in kidney diseases: are we there yet?
John Sayer, Belgium

6. Clinical cases for the adult nephrologist: another quizz to end the session
John Sayer, United Kingdom
Emilie Cornec Le Gall, France

ACUTE KIDNEY INJURY

Chairs: Valerie Luyckx, Vincenzo Cantaluppi, Turgay Saritas

1. Clinical implications of basic science discoveries in AKI
Turgay Saritas, Germany

2. Sepsis-associated AKI and targets for extracorporeal blood purification therapies
Marco Fiorentino, Italy

3. How to do peritoneal dialysis for AKI?
Daniela Ponce, Brazil

4. How to prescribe and troubleshoot CKRT in critically ill patients?
John Prowle, United Kingdom

5. AKI management: challenging cases and panel discussion
All speakers and audience
CME 7
ELECTROLYTES AND UROLITHIASIS

Chairs: Olivier Bonny, Jean-Philippe Bertocchio, Ewout Hoorn

1. Tubulopathies: should we sequence everyone?
   Franz Schafer, Germany

2. Withholding medications or restricting dietary potassium to prevent hyperkalemia; Still a good idea?
   Juan Jesus Carrero, Sweden

3. Uric acid nephropathy: does it exist?
   Stefanie Steiger, Germany

4. X-linked hypophosphatemia: who should we treat and for how long?
   Justine Bacchetta, France

5. Alkali therapy for kidney protection in kidney transplant recipients with metabolic acidosis.
   Nilufar Mohebbim Switzerland

HAND-ON COURSE ON RENAL BIOPSY (AFTERNOON COURSE)

This course will be done using MAX-CORE biopsy systems; please consider that similar products from other companies are available on the market.

Chairs: Emily McQuarrie, Loreto Gesualdo

1. Introduction
   Emily McQuarrie, United Kingdom

2. Indications and epidemiology of native kidney biopsy
   Colin Geddes, United Kingdom

3. Practical aspect of Biopsy
   Candice Roufosse, United Kingdom

4. Complications of Kidney Biopsy
   Loreto Gesualdo, Italy

5. US demonstration
   Mario Meola, Italy

6. Biopsy demonstration and Practice
   Emily McQuarrie, United Kingdom
   Colin C. Geddes, United Kingdom
   Loreto Gesualdo, Italy
   Stefanie Heidenreich, Germany
   Adele Mitrotti, Italy
   Michele Rossini, Italy
   Mauro Forcella, Italy
   Antonio Granata, Italy

HAND-ON COURSE ON CATHETER PLACEMENT (AFTERNOON COURSE)

This course will be done using Palindrome™ catheter family; please consider that similar products from other companies are available on the market.

Chairs: Kate Stevens, Maurizio Gallieni

1. Introduction
   Kate Stevens, United Kingdom

2. Minimising catheter associated infection
   Maria Guedes Marques, Portugal

3. Kinking and Tip position
   Carlo Lomonte, Italy

4. Assessment and management of central vein stenosis and atrial thrombus
   Sokratis Stoumpos, United Kingdom

5. Discussion

6. Demonstration Tunnelled Line Insertion & Non tunnelled Line insertion
   Maurizio Gallieni, Italy

7. Practice
   Kate Stevens, United Kingdom
   Maurizio Gallieni, Italy
   Maria Guedes Marques, Portugal
   Jennifer Lees, United Kingdom
   Carlo Lomonte, Italy
   Sokratis Stoumpos, United Kingdom
   Peter Thomson, United Kingdom
   Paolo Ria, Italy
   Paolo Luca Maria, Italy
   Ioannis Giannikouri, Greece

The 2023 Hands-on courses will be done using the following ultrasound devices:
SonoEye P2, Resona I9 and M9, CERBERO 4.0, Ultrasound System 3300 and CK50.
Please consider that similar products from other companies are available on the market.
**1 Welcome words**
Piergiorgio Messa, Local Congress President, Italy
Loreto Gesualdo, Honorary Local Congress President, Italy

**2 Presidential address**
Christoph Wanner, ERA President, Germany

**3 Diplomas and thanks**
Christoph Wanner, ERA President to Francesca Mallamaci, Scientific Committee Chair

**4 ERA Awards**
Christoph Wanner ERA President
- ERA Award for Outstanding clinical contributions to nephrology
  Vladimir Tesar, Czech Republic
- ERA Award for Outstanding basic science contributions to nephrology
  Tobias B. Huber, Germany
- ERA Award for Research excellence in nephrology
  Maria Dolores Sanchez-Niño, Spain
- ERA Rosanna Gusmano Award for Young Investigators in basic science
  Christoph Kuppe, Germany
- ERA Stanley Shaldon Award for Young Investigators in translational science
  Stefanie Steiger, Germany & Edouard Fu, The Netherlands
- ERA Eberhard Ritz Award for Young Investigators in clinical science
  Olivier Aubert, France

**5 Honorary Membership**
Christoph Wanner, ERA President, Germany to Carmine Zoccali, Italy

**6 Introduction to the Welcome Lecture**
Francesca Mallamaci, Scientific Committee Chair, Italy

**7 Welcome Lecture**
Leonardo in Milano, Pietro Marani, Italy
### CONTENT & DAILY INDEX

#### SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Day</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday - June 15, 2023</td>
<td>5</td>
</tr>
<tr>
<td>Friday - June 16, 2023</td>
<td>11</td>
</tr>
<tr>
<td>Saturday - June 17, 2023</td>
<td>26</td>
</tr>
<tr>
<td>Sunday - June 18, 2023</td>
<td>42</td>
</tr>
</tbody>
</table>

### 16 FRI DAY AT A GLANCE

- **WHAT’S NEW IN THE MANAGEMENT OF PRIMARY GLOMERULAR DISEASES?**
- **ENSURING OPTIMAL TREATMENTS TO DELAY PROGRESSION CKD IN ROUTINE CLINICAL PRACTICE**
- **UPDATES ON CURRENT MANAGEMENT OF CKD – WHAT’S NEW AND WHERE ARE WE GOING**
- **ERA REGISTRY**
- **THE RENAL RIDDLE**
- **DILEMMAS IN DIALYSIS**
- **REJECTION REJECTED**
- **LEARN BY PRACTICE ON ANEMIA IN CKD**
- **THE ERA PROJECT ON BRAIN AND KIDNEY INTERACTION (CONNECT): PRESENT AND FUTURE**
- **NON RESOLVING INFLAMMATION: HOW A DEFENSIVE MECHANISM TRANSFORMS INTO A MAJOR THREAT TO HUMAN HEALTH BASIC / TRANSLATIONA**
- **LATE BREAKING CLINICAL TRIALS**
- **DECEASED DONOR SELECTION: NEW APPROACHES AND SOLUTIONS**
- **CLASSIC AND NON-CLASSIC PLAYERS IN BONE AND VASCULAR DISORDERS IN CKD**
- **ADVANCES IN RENAL PHYSIOLOGY 1: NOVEL ‘INTRACRINE’ REGULATORS OF TUBULAR TRANSPORT**
- **ENDOCRINE AND BONE -RELATED STONES**
<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>THE ART OF STARING AT URINE: STUDIES IN IGA NEPHROPATHY</td>
<td>18</td>
</tr>
<tr>
<td>CALCIUM CONUNDRUMS AND VITAMIN D DILEMMAS</td>
<td>18</td>
</tr>
<tr>
<td>AKI: OUTCOMES</td>
<td>19</td>
</tr>
<tr>
<td>CREATIVE LABS I: THE CHECK LIST OF SETTING UP A CLINICAL TRIALS</td>
<td>19</td>
</tr>
<tr>
<td>HOT TOPICS IN HEMODIALYSIS</td>
<td>20</td>
</tr>
<tr>
<td>CKD PREVALENCE AND PROJECTIONS - PREPARING FOR THE STORM?</td>
<td>20</td>
</tr>
<tr>
<td>LONG-TERM COMPLICATIONS IN RENAL TRANSPLANTATION</td>
<td>20</td>
</tr>
<tr>
<td>LUPUS NEPHRITIS; STILL MANY UNKNOWNS IN THE TREATMENT</td>
<td>20</td>
</tr>
<tr>
<td>HYPERTENSION IN CKD: PROGRESS IN PATHOPHYSIOLOGY AND THERAPEUTIC INNOVATION</td>
<td>21</td>
</tr>
<tr>
<td>OBSERVATIONAL STUDIES: WHERE CORRELATION AND CAUSATION GET CONFUSED</td>
<td>21</td>
</tr>
<tr>
<td>YOU HAVE TO RECOGNIZE IT BEFORE YOU SEE IT</td>
<td>21</td>
</tr>
<tr>
<td>HYPERTENSION: THE ROLE OF 24H ABPM AND REMOTE MONITORING</td>
<td>21</td>
</tr>
<tr>
<td>CREATIVE LABS II: ETHICS IN PUBLICATION (RESEARCH ETHICS AND GOOD CLINICAL PRACTICE)</td>
<td>22</td>
</tr>
<tr>
<td>PROGRESS IN THE PATHOGENESIS OF NUTRITIONAL DISORDERS IN CKD</td>
<td>23</td>
</tr>
<tr>
<td>ELECTRONIC FILES IN NEPHROLOGY: FROM DATA COLLECTION TO ADVANCED DATA MANAGEMENT</td>
<td>23</td>
</tr>
<tr>
<td>EXPANDING THE DONOR POOL: A NEW AND BIG CHALLENGE</td>
<td>23</td>
</tr>
</tbody>
</table>
FRI
FRIDAY - JUNE 16, 2023

NOVEL TREATMENT STRATEGIES FOR RENOPROTECTION
MIND THE KIDNEYS: THE RELATIONSHIP BETWEEN CKD AND COGNITION
SMALL PATIENTS, BIG DATA
AGE AND ACCESS
IMMUNOSUPRESSED CKD PATIENT IN THE ICU
MODERATED ORALS + FOCUSED ORALS

CONTENT & DAILY INDEX

THURSDAY - JUNE 15, 2023 5

FRI
FRIDAY - JUNE 16, 2023 11

SATURDAY - JUNE 17, 2023 26

SUNDAY - JUNE 18, 2023 42
Symposium 2.1
WHAT’S NEW IN THE MANAGEMENT OF PRIMARY GLOMERULAR DISEASES?
Chairs: Mehmet Sukru Sever & Serhan Z. Tugular
1. IgA nephropathy
   Rosanna Coppo, Italy
2. Membranous nephropathy
   Gema Fernandez, Spain
3. Focal segmental glomerulosclerosis
   Paola Romagnani, Italy

Symposium 3.1
ENSURING OPTIMAL TREATMENTS TO DELAY PROGRESSION CKD IN ROUTINE CLINICAL PRACTICE
Chairs: Aikaterini Papagianni & Albert Ong
1. Non-steroidal MRAs to the clinics: present and the future
   Patrick Mark, United Kingdom
2. Cost effectiveness of implementing SGLT2 inhibitors in routine clinical practice
   Hiroshi Nishi, Japan (JSN)
3. Optimizing the use of RASi in advanced CKD
   Ana Carina Ferreira, Portugal

Symposium 6.2
UPDATES ON CURRENT MANAGEMENT OF CKD – WHAT’S KNOWN AND WHERE ARE WE GOING
Chairs: Francesca Mallamaci & Markus Ketteler
1. Development of new therapies to combat kidney disease
   Masaomi Nangaku, Japan (ISN)
2. Non-steroidal MRAs in CKD
   Alessandro Zuccolà, Italy
3. CKD, stroke and dementia: are there good news?
   Dearbhla Kelly, United Kingdom

Symposium 0.2
ERA REGISTRY
Chairs: Vianda Stel & Alberto Ortiz
1. Inherited kidney disease project
   Alberto Ortiz, Spain
2. Changes in epidemiology of KRT in 2020 – the first year of the COVID-19 pandemic
   Kitty Jager, United Kingdom
3. Trajectories of end-of-life in older patients with advanced CKD
   Nick Chesnaye, The Netherlands
Free Communication 23  
**THE RENAL RIDDLE**  
**Chairs:** Giovanbattista Capasso & Ionut Nistor  
**Mini Lecture:** Mehmet Kanbay, Turkey  
**FATTY KIDNEY AND ITS IMPLICATIONS FOR INFLAMMATION AND CKD**  
Peter Forster, United States of America  
**AMINOPEPTIDASE A REGULATES ACUTE ANGIOTENSIN DEPENDENT HYPERTENSION**  
Wisam Bitar, Finland  
**Mini Lecture:** Giovanni Tripepi, Italy  
**THE RENAL RIDDLE**  
**Chairs:** Giovanbattista Capasso & Ionut Nistor  
**Mini Lecture:** Mehmet Kanbay, Turkey  
**FATTY KIDNEY AND ITS IMPLICATIONS FOR INFLAMMATION AND CKD**  
Peter Forster, United States of America  
**AMINOPEPTIDASE A REGULATES ACUTE ANGIOTENSIN DEPENDENT HYPERTENSION**  
Wisam Bitar, Finland  
**Mini Lecture:** Giovanni Tripepi, Italy  
**EFFECT OF THE DIALYSATE TEMPERATURE ON CLINICAL OUTCOMES IN HEMODIALYSIS PATIENTS**  
Toshiyuki Imasawa, Japan  
**IS GFR DECLINE INDUCED BY SGLT-2 INHIBITOR OF CLINICAL IMPORTANCE?**  
Dennis Kannenkeril, Germany

Free Communication 13  
**DILEMMAS IN DIALYSIS**  
**Chairs:** Björn Meijers & Halima Resic  
**Mini Lecture:** Raymond Vanholder, Belgium  
**IS THERE ANY PLACE IN THE FUTURE FOR HOME HAEMODIALYSIS?**  
Wisam Bitar, Finland  
**Mini Lecture:** Giovanni Tripepi, Italy  
**EFFECT OF COMORBIDITIES ON HEALTHCARE EXPENDITURES FOR PATIENTS ON KIDNEY REPLACEMENT THERAPY IN A FRENCH COHORT.**  
Cécile Couchoud, France

Free Communication 19  
**REJECTION REJECTED**  
**Chairs:** Sandrine Florquin & Piergiorgio Messa  
**Mini Lecture:** Guillaume Canaud, France  
**HOW TO MANAGE TRANSPLANT CANDIDATES WITH PRIMARY FSGS FOR A FIRST OR AFTER MULTIPLE TRANSPLANTS**  
Motoshi Hattori, Japan  
**CIRCULATING NEPHRIN AUTOANTIBODIES IN PATIENTS WITH POST-TRANSPLANT RECURRANCE OF PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS**  
Teresa Vázquez, Spain  
**TOCILIZUMAB INDUCTION THERAPY IN KIDNEY TRANSPLANTATION**  
Sherzod Abdullaev, Uzbekistan  
**EXCELLENT EFFICACY AND BENEFICIAL SAFETY DURING FIVE YEAR FOLLOW-UP OF RAPID STEROID WITHDRAWAL AFTER RENAL TRANSPLANTATION (HARMONY STUDY)**  
Julian Stumpf, Germany

**LEARN BY PRACTICE ON ANEMIA IN CKD**  
**Chair:** Mario Cozzolino  
1. Learn by Practice on Anemia in CKD  
Livia del Vecchio, Italy  
2. Learn by Practice on Anemia in CKD  
Socratis Stoumpos, United Kingdom
HALL AMBER 6  10:00-11:00 (CEST)

Symposium 0.9
THE ERA PROJECT ON BRAIN AND KIDNEY INTERACTION (CONNECT):
PRESENT AND FUTURE
Chair: Giovambattista Capasso.

1. Panel Discussion.
   Ivan Rychlik, Czech Republic
   Marion Pepin, France
   Olivier Godfray, France
**SCIENTIFIC PROGRAMME**

**FRI 16**

**HALL GOLD (PLENARY) 11:00-11:45 (CEST)**

**Plenary Lecture 1**

**NON RESOLVING INFLAMMATION: HOW A DEFENSIVE MECHANISM TRANSFORMS INTO A MAJOR THREAT TO HUMAN HEALTH BASIC / TRANSLATIONAL**

**Chairs:** Albert Ong & Danilo Fiser

Non resolving inflammation: How a defensive mechanism transforms into a major threat to human health basic / translational

Alberto Montovani, Italy

**HALL GOLD (PLENARY) 12:00-13:15 (CEST)**

**Symposium 0.1**

**LATE BREAKING CLINICAL TRIALS**

**Chairs:** Giuseppe Remuzzi & Ana Carina Ferreira

1. THE SGC ACTIVATOR RUNCACIGUAT IS ASSOCIATED WITH A STRONG REDUCTION IN UACR AND GOOD TOLERABILITY IN CKD PATIENTS WITH OR WITHOUT AN SGTL2 INHIBITOR
   Ronald Gansevoort, The Netherlands

2. INTRANASAL NICLOSAMIDE FOR PRE-EXPOSURE PROPHYLAXIS AGAINST SARS-COV-2 IN A VULNERABLE, LARGELY VACCINATED RENAL PATIENT POPULATION
   Rona Smith, United Kingdom

3. FACTOR XI-A INHIBITION BY OSOCIMAB IN PATIENTS WITH END-STAGE KIDNEY DISEASE ON HEMODIALYSIS (ESKD-HD)
   Wolfgang Winkelmayer, United States of America

4. CONVINCE: HAEMODIAFILTRATION VERSUS HAEMODIALYSIS FOR MORTALITY, CARDIOVASCULAR EVENTS, AND HOSPITALISATION IN ADULT PATIENTS
   Peter J. Blankestijn, The Netherlands

5. LONG-TERM RENAL BENEFIT OVER 2 YEARS WITH NEFECON VERIFIED: THE NEFIGARD PHASE III FULL TRIAL RESULTS
   Richard Lafayette, United States of America

**HALL AUDITORIUM 12:00-13:15 (CEST)**

**Symposium 5.1**

**DECEASED DONOR SELECTION: NEW APPROACHES AND SOLUTIONS**

**Chairs:** Christophe Mariat & Marta Crespo

1. How to select the right donor for the right recipient: guidelines and other considerations.
   Piergiorgio Messa, Italy

2. Ethical issue in kidney transplantation
   Mehmet Sukru Sever, Turkey

3. New approaches to improve graft viability and implementation.
   Gabriel Oniscu, Sweden

**HALL SPACE 1 & 2 12:00-13:15 (CEST)**

**Symposium 4.1**

**CLASSIC AND NON-CLASSIC PLAYERS IN BONE AND VASCULAR DISORDERS IN CKD**

**Chairs:** Smeeta Sinha & Pieter Evenepoel

1. Links Between Bone Fragility Fractures and Vascular Disorders
   Jorge Cannata-Andia, Spain

2. Role of Vitamin K in CKD-related Osteoporosis and Vascular Calcification
   Maria Fusaro, Italy

3. FGF-23 and CV comorbidities – Vit D or CaSR-agonists
   Rainer Oberbauer, Austria
Symposium 1.2
ADVANCES IN RENAL PHYSIOLOGY 1: NOVEL 'INTRACRINE' REGULATORS OF TUBULAR TRANSPORT
Chairs: Robert John Unwin & Francesco Pesce
1. Renal autocrine and paracrine signaling
   Helle Praetorius, Denmark
2. Pharmacological modulation of sodium-glucose transporters to enhance ultrafiltration in peritoneal dialysis
   Karin Bergling, Sweden
3. Towards clinical application of tubular transport regulators
   Ewout Hoorn, The Netherlands

Symposium 1.1
ENDOCRINE AND BONE-RELATED STONES
Chairs: Giovanni Gambaro & Marina Noris
1. Nephrolithiasis in hyperparathyroidism
   Giuseppe Vezzoli, Italy
2. Nephrolithiasis due to metabolic bone disease
   Nilufar Mahebbi, Switzerland
3. Renal stones and vitamin D: a puzzling association
   Shabbir Moochhala, United Kingdom

Free Communication 06
THE ART OF STARING AT URINE: STUDIES IN IGA NEPHROPATHY
Chairs: Antonello Pani & Kate Stevens
Mini Lecture: Paolo Schena, Italy
EFFECTS OF CALCIIMMETICS ON LVH
VITAMIN D AND PARATHYROID HORMONE PREDICT INCIDENT MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS STARTING HAEMODIALYSIS: A REAL-WORLD ANALYSIS
Anirudh Rao, United Kingdom
NO DIFFERENCES IN ALL-CAUSE OR CARDIOVASCULAR MORTALITY BETWEEN DIALYSEATE CALCIUM OF 1.25 AND 1.50MMOL/L: RESULTS FROM A EUROPEAN HEMODIALYSIS COHORT
Karlien ter Meulen, The Netherlands
25 HYDROXYVITAMIN D ASSOCIATES WITH GASTROINTESTINAL BLEEDING IN DIALYSIS
John Larkin, United States of America
ASSOCIATION BETWEEN CKD-MBD AND SYMPTOM BURDEN IN OLDER PATIENTS WITH ADVANCED CKD – RESULTS FROM THE EQUAL STUDY
Lorenza Magagnoli, Italy
Symposium 7.2
AKI: OUTCOMES

Chairs: Nick Selby & Marlies Ostermann

1. Mortality risk in patients with AKI - High risk in the long-term as well?
   Ziad Massy, France

2. Recurrent AKI after recovery of the first attack
   Eva Rodríguez, Spain

3. Transition from AKI to CKD: Transition from bad to worse
   Joana Gameiro, Portugal

CREATIVE LABS I: THE CHECK LIST OF SETTING UP A CLINICAL TRIALS

Marcela Fajardo-Moser, Germany
SCIENTIFIC PROGRAMME

HALL GOLD (PLENARY) 14:45-16:00 (CEST)
Symposium 4.7
HOT TOPICS IN HEMODIALYSIS
Chairs: Francesco Locatelli & Ligia Petrica
1. Hemodialysis hypotension in 2023: a completely preventable complication? Bernard Canaud, France
2. Hemodialfiltration, Expanded Hemodialysis: which of them for the next future? Francesco Locatelli, Italy
3. Home therapies - lessons from the Netherlands Alfiero Abrahams, The Netherlands

HALL AUDITORIUM 14:45 - 16:00 (CEST)
Symposium 3.2
CKD PREVALENCE AND PROJECTIONS - PREPARING FOR THE STORM?
Chairs: Ana Carina Ferreira & Davide Bolignano
1. European burden of CKD in a global perspective Boris Bikbov, Italy
2. Population ageing and how it will impact on CKD epidemics Kitty Jager, The Netherlands
3. Getting ready: how will this impact on the profession of nephrology and on the delivery of nephrology care? Fergus Caskey, United Kingdom

HALL SPACE 1 & 2 14:45 - 16:00 (CEST)
Symposium 5.4
LONG-TERM COMPLICATIONS IN RENAL TRANSPLANTATION
Chairs: Bente Jespersen & Ilaria Gandolfini
1. Parathyroidectomy or calcimimetics for tertiary hyperparathyroidism after kidney transplantation? Martin H. de Borst, The Netherlands
2. Prevention and treatment of BK polyoma virus infection: the new TTS guidelines Hans Hirsch, Switzerland
3. Kidney Fibrosis: Pathogenesis, Biomarkers and Therapeutic Targets Rikke Nørregaard, Denmark

HALL SPACE 3 & 4 14:45 - 16:00 (CEST)
Symposium 2.3
LUPUS NEPHRITIS; STILL MANY UNKNOWNS IN THE TREATMENT
Chairs: Annette Bruchfeld & Loreto Gesualdo
1. Immunoogy and inflammation in lupus nephritis Eleni Frangou, Cyprus
2. Refractory lupus nephritis: When, why and how to treat Safak Mirogiu, Turkey
3. Kidney Replacement Therapy and Outcomes in patients with Lupus nephritis Vladimir Tesar, Czech Republic
Symposium 6.1
HYPERTENSION IN CKD: PROGRESS IN PATHOPHYSIOLOGY AND THERAPEUTIC INNOVATION

Chairs: Beatriz Fernandez Fernandez & Robert Ekart

1. Treatment resistant hypertension in predialysis CKD patients: An epidemiological and Clinical Perspective
   Andrzej Wieczek, Poland

2. Hypertension and the microbiome in CKD: the critical kidney- gut link
   Natalia G Vallianou, Greece

3. Renal denervation in 2023. Striking a balance
   Roland E Schmieder, Germany (ESH)

Free Communication 9
OBSERVATIONAL STUDIES: WHERE CORRELATION AND CAUSATION GET CONFUSED

Chairs: Gianluigi Tripepi & Anneke Kramer

Mini Lecture: Edouard Fu, The Netherlands

1. Drawing causal inference from observational studies in nephrology
   Nu Thuy Dung Tran, France

2. Prediction of all-cause mortality for chronic kidney disease patients using four models of machine learning
   Lei Tang, P.R. China

3. Estimated glomerular filtration rate by five differing measures, race, genetic risk and prediction of cardiovascular disease and mortality
   Ryosuke Fujii, Italy

4. Integrated kidney markers and cardiovascular mortality: a survival analysis in UK Biobank
   Simon Kok Jensen, Denmark

5. Acute kidney injury duration and 20-year risk of chronic kidney disease and cardiovascular disease: a population-based cohort study
   Melvy June Balasa, The Philippines

Symposium 6.4
HYPERTENSION: THE ROLE OF 24H ABPM AND REMOTE MONITORING

Chairs: Charles Ferro & Maria Pippias

1. Is feasible to employ 24h ABPM in clinical practice?
   Claudia Torino, Italy

2. Home tele-monitoring and management support of blood pressure
   Ikechi Okpechi, Canada

3. Home BP monitoring – can it ever replace 24h ABPM?
   Rajiv Agarwal, United States
HALL AMBER 5  14:45 - 16:00 (CEST)

CREATIVE LABS II: ETHICS IN PUBLICATION (RESEARCH ETHICS AND GOOD CLINICAL PRACTICE)

Valerie A. Luyckx, Switzerland
**Symposium 3.4**
**PROGRESS IN THE PATHOGENESIS OF NUTRITIONAL DISORDERS IN CKD**

**Chairs:** Peter Stenvinkel & Carla Avesani

1. Renal nutrition in the OMIC era
   Peter Stenvinkel, Sweden
2. Reducing salt and promoting dietary K intake; the way to go?
   Manuel Ferraro, Italy
3. Modulation of dietary amino acids to retard the progression of CKD
   Laetitia Koppe, France

**Symposium 4.8**
**ELECTRONIC FILES IN NEPHROLOGY: FROM DATA COLLECTION TO ADVANCED DATA MANAGEMENT**

**Chairs:** Mario Cozzolino & Tamara Jemcov

1. The British health system database and the electronic management of patients with kidney diseases
   Dorothea Nitsch, United Kingdom
2. Next generation digital pathology in Nephrology
   Laura Barisoni, United States of America
3. The future is now: advanced electronic data system with automatic risk assessment and clinical alerts
   Stefano Stuard, Germany

**Symposium 5.3**
**EXPANDING THE DONOR POOL: A NEW AND BIG CHALLENGE**

**Chairs:** Piergiorgio Messa & Anna Julie Peired

   Christophe Mariat, France
2. Growing human organs in a dish and in living animals: what is the future of organ transplantation?
   Christodoulos Xinaris, Italy
3. The bioartificial kidney: what are the prospects?
   Anna Julie Peired, France

**Symposium 2.4**
**NOVEL TREATMENT STRATEGIES FOR RENOPROTECTION**

**Chairs:** Sokratis Stoumpos & Eleni Frangou

1. Stimulating the protective arm of RAAS
   Ariela Benigni, France
2. Extracellular vesicles as new theranostic tools
   Lilach Lerman, United States of America
3. Targeting the RNA-binding proteins: a new boundary?
   Michael Ignarski, Germany
Free Communication 21
MIND THE KIDNEYS: THE RELATIONSHIP BETWEEN CKD AND COGNITION
Chairs: Davide Viggiano & Marion Pepin
Mini Lecture: Evangelia Ntounousi, Greece
CKD, STROKE AND DEMENTIA – AN UNHOLY TRINITY?
ACUTE KIDNEY INJURY AND THE RISK OF DEMENTIA; THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. Hong Xu, Sweden
EFFECTIVENESS AND SAFETY OF AXPABAN, RIVAROXABAN AND WARFARIN IN PATIENTS WITH ADVANCED CKD AND ATRIAL FIBRILLATION: NATIONWIDE US COHORT STUDY Edouard Fu, The Netherlands
Mini Lecture: Stella Stabouli, Greece (ESPN)
SUBCLINICAL CARDIOVASCULAR DISEASE IN CHILDREN WITH CHRONIC KIDNEY DISEASE. DOES IT MATTER FOR ADULT OUTCOMES?

Free Communication 2
SMALL PATIENTS, BIG DATA
Chairs: Rukksa Shroff & Gema Ariceta
Mini Lecture: Gema Ariceta
USE OF COMPLEMENT INHIBITORS IN PAEDIATRIC PATIENTS
FIRST INTERIM ANALYSIS OF THE INTERNATIONAL DISTAL RENAL TUBULAR ACIDOSIS REGISTRY Marta Giaccari, Italy
ALPORT SYNDROME NATURAL HISTORY FROM THE RADAR REGISTRY: ASSOCIATIONS WITH GENE, VARIANT TYPE AND SEX Katie Wong, United Kingdom
ECYSCHO: A EUROPEAN COHORT DEDICATED TO CYSTINOSIS Servais Aude, France
SYSTEMIC OXALOSIS: AN OVERVIEW OF THE FINDINGS AND PREVALENCE IN PRIMARY HYPEROXALURIA Deesker Lisa, The Netherlands

Free Communication 15
AGE AND ACCESS
Chairs: Marianne Verhaar & Carlo Lomonte
Mini Lecture: Natalie Ebert, Germany
ELDERLY PATIENT WITH ESKD: MANY MORE PROBLEMS THAN THE SOLUTIONS
A META-ANALYSIS OF VASCULAR ACCESS OUTCOMES IN HEMODIALYSIS PATIENTS OVER 75 YEARS OLD Alexandra Ntemka, Greece
DETERMINATION OF PREDICTORS OF OUTCOMES FOLLOWING VASCULAR ACCESS CONVERSION: WHICH PATIENTS BENEFIT MOST? Amun Hofmann, Austria
ARTERIOVENOUS FISTULA BLOOD FLOW ESTIMATION THROUGH AI MODEL EXPLOITING PATIENT’S ROUTINELY COLLECTED DATA Francesco Bellocchio, Italy
EVALUATION OF REMOTE MONITORING OF HAEMODIALYSIS VASCULAR ACCESS FOR PREDICTION OF STENOSIS AND THROMBOTIC VASCULAR EVENTS Dimitrios Poulikakos, United Kingdom

Symposium 7.3
IMMUNOSUPPRESSED CKD PATIENT IN THE ICU
Chairs: Norbert Lameire & Hans-Joachim Anders
2. AKI superimposed on CKD in the ICU setting Norbert Lameire, Belgium
3. Who will manage the patient: Intensivist or the nephrologist? Bairbre McNicholas, Ireland
<table>
<thead>
<tr>
<th>Time</th>
<th>Hall Amber 6</th>
<th>Hall Focused Orals</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:45 (CEST)</td>
<td>MODERATED ORALS 1.1</td>
<td>FOCUSED ORALS 1.1</td>
</tr>
<tr>
<td>12:00 - 13:15 (CEST)</td>
<td>MODERATED ORALS 1.2</td>
<td>FOCUSED ORALS 1.2</td>
</tr>
<tr>
<td>14:45 - 16:00 (CEST)</td>
<td>MODERATED ORALS 1.3</td>
<td>FOCUSED ORALS 1.3</td>
</tr>
<tr>
<td>17:00 - 18:15 (CEST)</td>
<td>MODERATED ORALS 1.4</td>
<td>FOCUSED ORALS 1.4</td>
</tr>
<tr>
<td>CONTENT &amp; DAILY INDEX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAMME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THURSDAY - JUNE 15, 2023</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>FRIDAY - JUNE 16, 2023</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>SATURDAY - JUNE 17, 2023</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>SUNDAY - JUNE 18, 2023</td>
<td>42</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SATURDAY - JUNE 17, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD PROGRESSION: BETWEEN THE OLD AND THE NEW</td>
</tr>
<tr>
<td>CLINICAL ISSUES IN PERITONEAL DIALYSIS I</td>
</tr>
<tr>
<td>2023 PEARLS OF NDT AND CKJ</td>
</tr>
<tr>
<td>ARE THERE NEW APPROACHES TO PREVENT AND TREAT AB-MEDIATED REJECTION</td>
</tr>
<tr>
<td>AN SGLT-2 INHIBITOR A DAY KEEPS THE DOCTOR AWAY</td>
</tr>
<tr>
<td>IDENTIFYING THE SWEET SPOT IN DIABETIC KIDNEY DISEASE</td>
</tr>
<tr>
<td>IS CKD PART OF THE LONG COVID SYNDROME?</td>
</tr>
<tr>
<td>LEARN BY PRACTICE ON HYPERKALEMIA IN CKD</td>
</tr>
<tr>
<td>CREATIVE LABS III: HOW TO RUIN YOUR PRESENTATION</td>
</tr>
<tr>
<td>ERA GENERAL ASSEMBLY</td>
</tr>
<tr>
<td>SEX, SCIENCE, MEDICINE AND GLOBAL (KIDNEY) HEALTH: WHERE WE ARE AND WHERE WE ARE GOING</td>
</tr>
<tr>
<td>C3 GLOMERULOPATH</td>
</tr>
<tr>
<td>VOLUME CONTROL REMAINS AN UNMET CLINICAL NEED IN CKD AND HEMODIALYSIS PATIENT</td>
</tr>
<tr>
<td>ADVANCES IN RENAL PHYSIOLOGY 2: NEWER HOMEOSTATIC MECHANISMS CONTROLLING KIDNEY FUNCTION</td>
</tr>
<tr>
<td>DIABETIC KIDNEY DISEASE UPDATE: GO BEYOND BORDERS</td>
</tr>
<tr>
<td>CONTEMPORARY AKI MANAGEMENT</td>
</tr>
</tbody>
</table>
MECHANISMS OF CKD PROGRESSION AND COMPLICATIONS: UNMASKING THE MYSTERY 34
PRE-EMPTIVE TRANSPLANTATION AND WHICH DONORS TO CHOOSE 34
SOMETHING RARE, SOMETHING SPECIAL 34
EGFR MEASUREMENTS IN CLINICAL PRACTICE 34
CKD DIAGNOSIS AND CARE IN THE PRIMARY CARE SETTING 35
INNOVATION IN DIALYSIS AND CLINICAL APPLICATION 36
UNMET NEEDS IN ADVANCED CKD: IMPROVING MAJOR SYMPTOMS AND QOL 36
CAN WE PREDICT GRAFT OUTCOMES? 36
POLYCYSTIC KIDNEY DISEASE: A MULTIFACETED DISEASE 36
DIALYSIS IN AKI: STILL AN ENDLESS STORY OR HAVE ISSUES BEEN CLARIFIED? 37
THE PERITONEAL PERSPECTIVE 37
NAVIGATING THE IGA NEPHROPATHY PATHWAY 37
TRANSPLANT TALES 37
ARMED CONFLICTS, KIDNEY PATIENTS AND NEPHROLOGISTS 38
EDUCATION IN NEPHROLOGY WHERE ARE WE GOING? (NPATH) 38
LATE BREAKING CLINICAL TRIAL 38
ASN HIGHLIGHTS 39
## CONTENT & DAILY INDEX

### SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Day</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday - June 15, 2023</td>
<td>5</td>
</tr>
<tr>
<td>Friday - June 16, 2023</td>
<td>11</td>
</tr>
<tr>
<td>Saturday - June 17, 2023</td>
<td>26</td>
</tr>
<tr>
<td>Sunday - June 18, 2023</td>
<td>42</td>
</tr>
</tbody>
</table>

### DAY AT A GLANCE

- Hypertension in Dialysis Patients: How to Measure It and How to Treat in 2023? (39)
- Pregnancy, Complications and Implications on Treatment (39)
- Heart Disease in CKD (39)
- Cardio-Vascular Complications in Renal Transplantation: Still a Neglected Field? (40)
- The Renal Revolution: Tackling Renal Disease on a Global Scale (40)
- Dialysis Insights and Innovations (40)
- The ANCA Vasculitis Variety Session (40)
- Creative Labs IV: Balancing Parenthood and Career (41)
Symposium 3.3
CKD PROGRESSION: BETWEEN THE OLD AND THE NEW
Chairs: Manuel Anibal A. Ferreira & Pieter Evenepoel
1. Low GFR and ageing; distinguish physiological and disease-related
   Pierre Delanaye, Belgium
2. Does COVID-19 really induce CKD?
   Rafael Kramann, Germany
3. Climate change, air pollution and kidney disease
   Valerie Luyckx, Switzerland

Symposium 4.2
CLINICAL ISSUES IN PERITONEAL DIALYSIS I
Chairs: Monika Lichodziejewska-Niemierko & Edwina Brown
1. Genetic variants that predict peritoneal ultrafiltration
   Rajnish Mehrotra, United States of America
2. Peritoneal dialysis in heart failure and in AKI. An evidence-based approach
   Daniela Ponce, Brazil
3. Hard facts: guidelines in peritoneal dialysis
   Mark Lambie, United Kingdom

Symposium 0.4
2023 PEARLS OF NDT AND CKJ
Chairs: Denis Fouque & Maria Soler
1. NDT Editor selects 2 Speakers from associate Editors
   Davide Bolignano, Italy
   Emilie Cornec-Le Gall, France
2. CKJ Editor selects 2 Speakers from the Editorial Board
   Parminder Judge, United Kingdom
   Andreas Kronbichler, United Kingdom

Symposium 5.5
ARE THERE NEW APPROACHES TO PREVENT AND TREAT AB-MEDIATED REJECTION?
Chairs: Bruno Watschinger & Z. Serhan Tuglular
1. Imlifidase for HLA-sensitised patients
   Andreas Kronbichler, United Kingdom
2. Complement inhibitors for the prevention and treatment of acute Ab-mediated rejection
   Marta Crespo, Spain
3. New concepts in the prevention and treatment of chronic Ab-mediated rejection
   Farsad Eskandary, Austria
**Free Communication 10**

**AN SGLT-2 INHIBITOR A DAY KEEPS THE DOCTOR AWAY**

**Chairs:** Richard Haynes & Samira Bell

**Mini Lecture:** David Wheeler, United Kingdom

**SGLT-2 INHIBITORS IN GLOMERULAR DISEASE**

**EFFECTS OF EMPAGLIFLOZIN ON KIDNEY AND CARDIAC MRI MEASURES IN PATIENTS WITH CHRONIC KIDNEY DISEASE**

Parminder Judge, United Kingdom

**EFFECTS OF EMPAGLIFLOZIN ON FLUID OVERLOAD IN CHRONIC KIDNEY DISEASE: AN EMPA-KIDNEY BIOMEDICINE SUBSTUDY**

Kaitlin Mayne, United Kingdom

**REASONS FOR DIALYSIS INITIATION AND SAFETY OF DAPA-CKD AMONG DIALYSIS PARTICIPANTS: NEW INSIGHTS FROM DAPA-CKD**

Hiddo Lambers Heerspink, The Netherlands

**FINERENONE ADDED TO RAS/SGLT2 BLOCKADE FOR NON-DIABETIC CHRONIC KIDNEY DISEASE. RESULTS OF A PRECLINICAL DOUBLE-BLUNDED RANDOMIZED CONTROLLED TRIAL**

Zhifui Zhu, Germany

---

**Free Communication 22**

**IDENTIFYING THE SWEET SPOT IN DIABETIC KIDNEY DISEASE**

**Chairs:** Esteban Porini & Mads Hornum

**Mini Lecture:** Tetsuhiro Tanaka, Japan (JSN)

**OXYGEN METABOLISM IN DIABETIC KIDNEY DISEASE**

Meng Yang, P.R. China

**EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM**

Viknesh Selvarajah, United Kingdom

**THE ROLE OF COMPLEMENT C5A RECEPTOR 1 IN DIABETIC KIDNEY DISEASE.**

**Free Communication 26**

**IS CKD PART OF THE LONG COVID SYNDROME?**

**Chairs:** Ronald Gansevoort & Marianne Verhaar

**Mini Lecture:** Faeq Husain-Syed, Germany

**AKI-CKD TRANSITION AFTER COVID-19 - HOW TO ASSESS?**

Nanditha Anandakrishnan, United States of America

**SECONDARY BACTERIAL AND FUNGAL INFECTIONS IN COVID-19 PATIENTS WITH ACUTE KIDNEY INJURY AND RELATION WITH CYTOKINE STORM SYNDROME**

Radulescu Daniela, Romania

**EFFICACY OF PAXLOVID WITHIN 5 DAYS Versus 5 DAYS AFTER DIAGNOSIS IN COVID-19 PATIENTS WITH CHRONIC KIDNEY DISEASE**

Wenjuan Yu, P.R. China

---

**LEARN BY PRACTICE ON HYPERKALEMIA IN CKD**

**Chair:** Pantelis Sarafidis

1. Learn by practice on Hyperkalemia in CKD

Andrea Galassi, Italy

2. Learn by practice on Hyperkalemia in CKD

Kieran McAfferty, United Kingdom
HALL AMBER 5  08:30-09:45 (CEST)

CREATIVE LABS III: HOW TO RUIN YOUR PRESENTATION
Jürgen Floege, Germany
The ERA 2023 Ordinary General Assembly (OGA) will take place on June 17, 2023, from 9.45 to 11.00 (CEST) in the Gold Room (Plenary) of the MICO – Milan Convention Centre - in Milan and virtually. Kindly note that active ERA Full* Members have voice and vote during the Assembly, instead active ERA Associate and Corporate Members have voice but cannot vote.

*Please note that only active ERA Full Members (not Corporate) may vote.

Part I - 09.30-09.40
OPENING
Welcome, Christoph Wanner (ERA President)

1. Minutes of the 59th General Assembly
   Ivan Rychlik (Secretary-Treasurer)

Part II - 09.40-10.30
2. Report from the President
   Christoph Wanner

3. Report from the Secretary-Treasurer
   Ivan Rychlik

4. Report from the Renal Science Chair
   Danilo Fliser

5. Report from the Clinical Nephrology Governance Chair
   Alberto Ortiz

Part III - 10.30-10.45
6. Election of the Ordinary Council Member (two vacancy)
   Christoph Wanner

7. Venue and date of the 2025 ERA Congress
   Christoph Wanner

8. Date and venue of the next General Assembly
   Ivan Rychlik

9. Any other business
   FERA awards,
   Ivan Rychlik

CLOSURE, Christoph Wanner

Plenary Lecture 2
SEX, SCIENCE, MEDICINE AND
GLOBAL (KIDNEY) HEALTH: WHERE WE ARE AND WHERE WE ARE GOING

Chairs: Roser Torra & Annette Bruchfeld

Sex, Science, Medicine and Global (kidney) Health: where we are and where we are going
Adeera Levin, Canada

Symposium 2.2
C3 GLOMERULOPATHY

Chairs: Dimitrios Goumenos & Claudia Ponticelli

1. C3 glomerulopathy - are some complement variants more pathogenic than others?
   Elena Giocechea De Jorge, Spain

2. Unravelling the involvement of complement in C3 glomerulopathy pathogenesis and implication in complement therapeutics
   Antonello Pani, Italy

3. Management strategies for recurrence of C3 glomerulopathy pre and post renal transplantation
   Manuel Praga, Spain
Symposium 4.5
VOLUME CONTROL REMAINS
AN UNMET CLINICAL NEED
IN CKD AND HEMODIALYSIS
PATIENT
Chairs: Gérard Michel London &
Nada Dimkovic
1. Sodium intake target in current CKD
   guidelines, instruments for self-
   measurement of urinary sodium and
   adherence to low salt diets
   Carmine Zoccali, Italy
2. Bio-impedance: a valid method to
   guide Ultrafiltration prescription during
   hemodialysis
   Ulrich Moissl, Belgium
3. How to diagnose and treat Heart Failure
   in dialysis patients
   Gérard Michel London, France

Symposium 1.3
ADVANCES IN RENAL
PHYSIOLOGY 2: NEWER
HOMEOSTATIC MECHANISMS
CONTROLLING KIDNEY
FUNCTION
Chairs: Hans-Joachim Anders & Rezan
Topaloglu
1. Circadian control of blood pressure
   rhythmicity
   Jessica Ivy, United Kingdom
2. Circadian control of nephron metabolism
   Yohan Bignon, Switzerland
3. New insight into Kidney-heart connection:
   magnesium as a player
   Francesco Trepiccione, Italy

Symposium 6.5
DIABETIC KIDNEY DISEASE
UPDATE: GO BEYOND BORDERS
Chairs: Fernandez Fernandez Beatriz &
Francesco Trevisani
1. Beyond trials: what can routine care data
tell us about the safety and effectiveness of
novel antidiabetic medications?
   Juan Jesus Carrero, Sweden
2. Predicting response to dapagliflozin: results
   in light of post-hoc analysis of DAPA-CKD
   Hiddo J L Heerspink, The Netherlands
3. Role of insulin therapy in DKD in the era of
   new antidiabetic drugs
   Esteban Porrini, Spain

Symposium 7.4
CONTEMPORARY AKI
MANAGEMENT
Chairs: Danilo Fliser & Jolanta Malyszko
1. Prediction of AKI: biomarkers, clinical
   models or both?
   Greet De Vlieger, Belgium
2. Artificial intelligence: Can it guide
   management of AKI patients?
   Jay L. Koyner, United States of America
3. As climate changes: EU get ready for
   subtropical causes of AKI
   Vivekanand Jha, India
**Free Communication 11**  
**MECHANISMS OF CKD PROGRESSION AND COMPLICATIONS: UNMASKING THE MYSTERY**  
**Chairs:** Goce Spasovski & Kathrin Eller  
**Mini Lecture:** Olga Balafa, Greece  
**SUBCLINICAL ACID RETENTION AND CKD PROGRESSION**  
**CAROTID PLAQUE THICKNESS PREDICTS CARDIOVASCULAR EVENTS AND DEATH IN PATIENTS WITH CHRONIC KIDNEY DISEASE**  
Sasha Saurbrey Bjergfelt, Denmark  
FIRST IDENTIFICATION AND CHARACTERIZATION OF MICROPLASTICS IN HUMAN KIDNEY AND URINE  
Ottavia Exacoustos, Italy  
BIO-CONDUCTIVITY MEASUREMENTS ENABLES PORTABLE AND SELF-ADMINISTERED CHRONIC KIDNEY DISEASE SCREENING AND MONITORING  
Eddie Wong, Hong Kong, P.R. China  
THE ROLE AND MECHANISM OF EZH2 IN VASCULAR CALCIFICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE  
Lin Pinglan, P.R. China

**Free Communication 18**  
**PRE-EMPTIVE TRANSPLANTATION AND WHICH DONORS TO CHOOSE**  
**Chairs:** David Ferenbach & Evangelia Ntounousi  
**Mini Lecture:** Vianda Stel, The Netherlands  
TRANSPLANT SURVIVAL BENEFIT – DOES IT APPLY TO ALL PATIENT SUBGROUPS?  
TRANSPLANTATION FUNCTION IN LIVING KIDNEY DONORS  
Ekamol Tantisattamo, United States of America  
EXTENDED VALIDATION OF THE IBOX IN REAL LIFE SETTING, DIFFERENT TRANSPLANT SYSTEMS AND CLINICAL TRIALS: THE IBOX EXTENDED TRIAL  
Sofia Naser, France  
NEXT GENERATION SEQUENCING: FROM BANFF SCORE MOLECULAR SIGNATURES AND CLASSIFIERS TO PREDICTED HISTOLOGICAL ARCHETYPES OF KIDNEY BIOPSPIES  
Esteban Cortes Garcia, France  
PROGNOSTIC VALUE OF A POSITIVE CROSSMATCH BEFORE DESENSITIZATION IN A COHORT OF HIGHLY-SENSITIZED PATIENTS  
Johan Noble, France

**Symposium 0.12**  
**EGFR MEASUREMENTS IN CLINICAL PRACTICE**  
**Chair:** Christophe Mariat  
1. Panel discussion  
Pierre Delanaye, Belgium  
Etienne Cavalier, Belgium  
Elke Schaeffner, Germany
CKD DIAGNOSIS AND CARE IN THE PRIMARY CARE SETTING

Chairs: Alexander Rosenkranz & Jaquie Finn

1. Panel Discussion
   Naresh Kanumilli, United Kingdom
   Daniel Gallego Zurro, Spain
   Kieran McCafferty, United Kingdom

This symposium is organized by the European Renal Association Curatorium (ERAC)
Symposium 4.4
INNOVATION IN DIALYSIS AND CLINICAL APPLICATION
Chairs: Carlo Basile & Maria Haller
1. Can the clearance of protein-bound uremic toxins be enhanced: theoretical and practical aspects.
   Peter Kotanko, United States of America
2. Innovations in dialysis: Mi-TRAM (Multi-compatible Implantable Toxin Removal Augmentation Module with fluid sensing) and new approaches
   Karin Gerritsen, The Netherlands
3. Incremental and twice-weekly longer hemodialysis. Testable in randomized clinical trials?
   Kamiar Kalantar-Zadeh, United States of America

Symposium 3.5
UNMET NEEDS IN ADVANCED CKD: IMPROVING MAJOR SYMPTOMS AND QOL
Chairs: Vianda Stel & Goce Spasovski
1. Pathogenesis and potential management strategies of uremia-induced cognitive impairment
   Davide Viggiano, Italy
2. Managing chronic pain in persons with CKD
   Samira Bell, United Kingdom
3. Fatigue in CKD: causes, consequences and management
   Lucile Parker Gregg, United States of America

Symposium 5.6
CAN WE PREDICT GRAFT OUTCOMES?
Chairs: Giuseppe Grandaliano & Carmen Lefaucheur
1. What the iBox is and is it useful for clinical decision-making?
   Oliver Aubert, France
   Nuria Montero, Spain
3. Will biomarkers help us to predict graft outcomes?
   Elisabeth Van Loon, Belgium

Symposium 1.5
POLYCYSTIC KIDNEY DISEASE: A MULTIFACETED DISEASE
Chairs: Giovambattista Capasso & Alessandra Boletta
1. Metabolic Reprogramming in Polycystic Kidney Disease
   Alessandra Boletta, Italy
2. Genetic Heterogeneity in Autosomal Dominant Polycystic Kidney Disease
   Emilie Corneec-LeGall, France
3. Metabolism and Dietary Interventions in ADPKD
   Roman-Ulrich Müller, Germany
Symposium 7.1
DIALYSIS IN AKI: STILL AN ENDLESS STORY OR HAVE ISSUES BEEN CLARIFIED?
Chairs: Marianne Verhaar & Laura Cosmai
1. STARRT-AKI Trial.
   Marlies Ostermann, United Kingdom
2. AKIKI 2 trial
   Stéphane Gaudry, France
3. What do metaanalyses say?
   Jan Kielstein, Germany

Free Communication 16
THE PERITONEAL PERSPECTIVE
Chairs: Angela Wang & Monika Lichodziejewska-Niemierko
Mini Lecture: Edwina Brown, United Kingdom (ISPD)
ASSISTED PD IN EUROPE: CALL FOR INCREASED AND EQUAL ACCESS
IN VIVO EVALUATIONS ON THE PROTECTIVE EFFECTS OF NEW FORMULATIONS FOR PERITONEAL DIALYSIS ADOPTING A POWERFUL MULTI-PHOTON MICROSCOPY BASED APPROACH
Luciano D’Apolito, Italy
PERITONEAL DIFFUSE PODOPLANIN EXPRESSION IS ASSOCIATED WITH SEVERE ARTERIOLOPATHY IN CHILDREN ON PERITONEAL DIALYSIS
Maria Bartosova, Germany
PERITONEAL DIALYSIS ADDITIVE REDUCES TRANS- AND INTRAPERITONEAL LOSS OF BLOOD MICROPARTICLE AND EXTRACELLULAR MATRIX PROTEINS IN A CONTROLLED CROSSOVER TRIAL
Fabian Eibensteiner, Austria
AUTOPHAGY PATHWAY ACTIVATION IN IMMUNE-INFLAMMATORY CELLS OF PERITONEAL DIALYSIS PATIENTS.
Gianluigi Zaza, Italy

Free Communication 4
NAVIGATING THE IGA NEPHROPATHY PATHWAY
Chairs: Gema Maria Fernandez Juarez & Vladimir Tesar
Mini Lecture: Hitoshi Suzuki, Japan (JSN)
THE PHENOTYPIC DIFFERENCE OF IGA NEPHROPATHY DEPENDS ON MOLECULAR MECHANISMS
INCIDENCE AND OUTCOMES OF KIDNEY REPLACEMENT THERAPY FOR END-STAGE KIDNEY DISEASE DUE TO PRIMARY GLOMERULONEPHRITIS IN THE ERA REGISTRY
Samar Abd ElHafeez, Egypt
INVESTIGATING THE ROLE OF CFH VARIANTS AND HAPLOTYPES AS A RISK FACTOR OF IGA NEPHROPATHY IN A FRENCH COHORT
Anna Duval, France
COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS
Kieran McCafferty, United Kingdom
MODELLING LONG-TERM OUTCOMES FOR PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN) FROM SHORT-TERM PROTEINURIA DATA
Mark Bensink, United States of America

Free Communication 20
TRANSPLANT TALES
Chairs: Orsolya Csepregi & Licia Peruzzi
Mini Lecture: Gaetano La Manna, Italy
THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANTATION
DONOR-DERIVED CELL-FREE DNA (DD-CDNA) AS A NON-INVASIVE BIOMARKER OF KIDNEY ALLOGRAFT REJECTION IN PEDIATRIC KIDNEY TRANSPLANTATION
Julien Hogan, France
BELATACEPT OUTCOMES IN PEDIATRIC KIDNEY TRANSPLANTATION: AN INTERNATIONAL MULTICENTER STUDY
Julien Hogan, France
IMPACT OF DARATUMUMAB & BELATACEPT ON HLA ANTIBODIES IN KIDNEY TRANSPLANT CANDIDATES WITH 100% CPRA: EARLY RESULTS OF ATTAIN (ITN09051)
Flavio Vincenti, United States of America
HEPATITIS B VIRUS REACTIVATION IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH BELATACEPT
Chloe Schwarz, France
ARMED CONFLICTS, KIDNEY PATIENTS AND NEPHROLOGISTS

Chairs: Raymond Vanholder & Mehmet Şükrü Sever

1. Being a nephrologist during an armed conflict
   Dmytro Ivanov, Ukraine

2. Case of displaced patients with kidney disease during the war in Ukraine
   Andrzej Wieczek, Poland

3. Learning to mitigate the impact of war - a report of Renal Disaster Relief Task Force of ERA
   Serhan Tuglu, Turkey

4. The most devastating pediatric renal disaster: the February 6th, 2023 Kahramanmaras/Turkiye earthquake
   Sevcan Azime Bakkaloglu, Turkey

Symposium 0.10
EDUCATION IN NEPHROLOGY WHERE ARE WE GOING? (NPATH)

Chairs: Loreto Gesualdo & Carlo Lomonte

1. Panel discussion
   Loreto Gesualdo, Italy
   Jose Ibeas, Spain
   Maurizio Gallieni, Italy

2. N-PATH Trainees Award Ceremony

Symposium 0.11
LATE BREAKING CLINICAL TRIALS

Chairs: Ronald Gansevoort & Roser Torra

1. 36-WK EFFICACY & SAFETY OF ATACICEPT 150MG IN THE ORIGIN RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY IN IGAN AND PERSISTENT PROTEINURIA
   Richard Lafayette, United States of America

2. GFR SLOPE AS A SURROGATE ENDPOINT FOR KIDNEY FAILURE IN CLINICAL TRIALS: AN UPDATED META-ANALYSIS
   Hiddo Lambers Heerspink, The Netherlands

3. EXERCISE DURING HEMODIALYSIS IN PATIENTS WITH CHRONIC KIDNEY FAILURE
   Gero Von Gersdorff, Germany
<table>
<thead>
<tr>
<th>Symposium 0.3</th>
<th>ASN HIGHLIGHTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs:</td>
<td>Susan Quaggin</td>
</tr>
</tbody>
</table>
| 1.           | Diabetic Kidney Disease Highlights  
Catherine Godson, United States of America |
| 2.           | Glomerular Diseases Highlights  
Kirk Campbell, United States of America |
| 3.           | Hypertension and Cardiorenal Disorders Highlights  
Karen Griffin, United States of America |

<table>
<thead>
<tr>
<th>Symposium 4.6</th>
<th>HYPERTENSION IN DIALYSIS PATIENTS: HOW TO MEASURE IT AND HOW TO TREAT IN 2023?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs:</td>
<td>Carmine Zoccali &amp; Pantelis Sarafidis</td>
</tr>
</tbody>
</table>
| 1.           | Assessing fluid volume in dialysis - is lung ultrasound the emerging standard?  
Pantelis Sarafidis, Greece |
| 2.           | BP target in hemodialysis patients: approach to an unsolved dilemma.  
Indranil Dasgupta, United Kingdom |
| 3.           | Dialysis and Home Dialysis in the pandemic years  
Helena Rydell, Sweden |

<table>
<thead>
<tr>
<th>Symposium 1.4</th>
<th>PREGNANCY, COMPLICATIONS AND IMPLICATIONS ON TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs:</td>
<td>Andreas Kronbichler &amp; Annette Bruchfeld</td>
</tr>
</tbody>
</table>
| 1.           | Safety and uncertainty of immunosuppression during pregnancy  
Sarah Gleeson, United Kingdom |
| 2.           | From preeclampsia to glomerular disease: spectrum of kidney diseases during pregnancy  
Annette Bruchfeld, Sweden |
| 3.           | CKD progression in transplanted and non-transplanted patients during and after pregnancy  
Giorgina Piccoli, France |

<table>
<thead>
<tr>
<th>Symposium 6.3</th>
<th>HEART DISEASE IN CKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs:</td>
<td>Lucia Del Vecchio &amp; José Manuel Valdivielso Revilla</td>
</tr>
</tbody>
</table>
| 1.           | A special approach for aortic stenosis (TAVI or SAVR) in CKD patients.  
Mattia Lunardi, Ireland |
| 2.           | Cardiac Metabolic Remodeling in CKD  
Dunja Aksentijevic, United Kingdom |
| 3.           | Heart and kidney disease: an intriguing liaison  
Anna Price, United Kingdom |
Symposium 5.7
CARDIO-VASCULAR COMPLICATIONS IN RENAL TRANSPLANTATION: STILL A NEGLECTED FIELD?
Chairs: Luuk Hilbrands & Gabriel Oniscu
1. Post transplant diabetes mellitus (PTDM): can it be actively prevented and how? Elisabeth Schwaiger, Austria
2. SGLT2 inhibitors: should be used for all renal transplant patients or when and in whom? Chiara Caletti, Italy
3. How to best treat post-Tx hypertension? What are the gap of knowledge? Jean-Michel Halimi, France (ESH)

Free Communication 8
THE RENAL REVOLUTION: TACKLING RENAL DISEASE ON A GLOBAL SCALE
Chairs: Samar Abd ElHafeez & Olga Balafa
Mini Lecture: Samar Abd ElHafeez, Egypt
CKD IN AFRICA: A PUBLIC HEALTH PRIORITY
PREVALENCE OF UNRECOGNIZED CHRONIC KIDNEY DISEASE IN THE LOLLAND-FALSTER HEALTH STUDY: A POPULATION-BASED STUDY IN A RURAL-PROVINCIAL AREA OF DENMARK. Ebba Mannheimer, Denmark
INTERNATIONAL VARIATIONS IN TRANSITION OF CARE PRACTICES AND TWO-YEAR OUTCOMES IN ADVANCED CHRONIC KIDNEY DISEASE Natalia Alencar de Pinho, France
DOES AV FISTULA FORMATION DELAY TIMING OF INITIATION OF KIDNEY REPLACEMENT THERAPY IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE? Luis Loureiro Harrison, United Kingdom
HEMOGLOBIN VARIABILITY AND ADVERSE CLINICAL EVENTS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE AND ANEMIA IN CONTINUOUS CARE Suguru Okami, Japan

Free Communication 14
DIALYSIS INSIGHTS AND INNOVATIONS
Chairs: Francesco Locatelli & Sanjin Racki
Mini Lecture: Jeong-Hoon Lim, Korea, Rep. of South (KSN)
THE CHANGING HEMODIALYSIS POPULATION IN A SINGLE UK CENTRE: A POST PANDEMIC PHENOMENON? Joanna McKinnell, United Kingdom
CVAE AND MORTALITY IN DIALYSIS PATIENTS: A NATIONWIDE RETROSPECTIVE COHORT STUDY. Sho Sasaki, Japan
THE ASSOCIATION OF PROLONGED QT INTERVALS WITH MORTALITY IN HEMODIALYSIS PATIENTS: A NATIONWIDE RETROSPECTIVE COHORT STUDY. Sheetal Chaudhuri, United States of America
ASSOCIATION OF PROLONGED QT INTERVALS WITH MORTALITY IN HEMODIALYSIS PATIENTS: A NATIONWIDE RETROSPECTIVE COHORT STUDY. Sheetal Chaudhuri, United States of America
THE LONG-TERM EFFECT OF A LUNG-ULTRASOUND INTERVENTION ON THE RISK FOR DEATH, HEART FAILURE AND MYOCARDIAL INFARCTION IN DIALYSIS PATIENTS. Claudia Torino, Italy

Free Communication 7
THE ANCA VASCULITIS VARIETY SESSION
Chairs: Anne Mühlig & Ariela Benigni
Mini Lecture: Anne Mühlig, Germany (YPNN-ESPA)
THE CALCIUM-SENSING RECEPTOR STABILIZES PODOCYTE FUNCTION IN PROTEINURIC HUMANS AND MICE Yusho Ueda, Japan
THE INVOLVEMENT OF Nrf2-MEDIATED ANTIOXIDANT SYSTEM IN MYELOPEROXIDASE-POSITIVE ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS Hatice Sahin, Turkey
COMBINED ACTIVITY AND CHRONICITY SCORE FOR PROGNOSTIC ASSESSMENT IN ANCA-ASSOCIATED VASCULITIS WITH GLOMERULONEPHRITIS Marta Casal Mauro, United States of America
PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES Jiahua Li, United States of America
CREATIVE LABS IV: BALANCING PARENTHOOD AND CAREER
Ana Carina Ferreira, Portugal

HALL AMBER 5
17:00-18:15 (CEST)
CONTENT & DAILY INDEX

SCIENTIFIC PROGRAMME

THURSDAY - JUNE 15, 2023  5

FRIDAY - JUNE 16, 2023  11

SATURDAY - JUNE 17, 2023  26

SUNDAY - JUNE 18, 2023  42

DIABETES IN CKD: THE KDIGO GUIDELINE UPDATE  43
GETTING THE PATIENTS VOICE HEARD  43
CLINICAL ISSUES IN PERITONEAL DIALYSIS II  43
RECIPIENT EVALUATION  43
DR. HOUSE, COULD IT BE LUPUS?  44
AKI ALCHEMY  44
THE GOOD, THE BAD, AND THE CYSTIC  44
BLOODY STONES!  44
PLENARY LECTURE 3 - YOUNG Awardees  45
NEPHROLOGY PEARLS (CLOSING SESSION)  45
Symposium 0.6
DIABETES IN CKD: THE KDIGO GUIDELINE UPDATE
Chairs: Mario Cozzolino & Michel Jadoul
1. Highlights from the 2022 Guideline Update on Diabetes in CKD: Implications of key publications (EMPA-KIDNEY, SMART-C, DELIVER, SURPASS)
   Katherine Turtel, United States of America
2. ADA/KDIGO and ADA/EASD Consensus Reports
   Peter Rossing, Denmark
3. Implementation of the KDIGO Diabetes Guideline for the European context
   Frederik Persson, Denmark

Symposium 3.6
GETTING THE PATIENTS VOICE HEARD
Chairs: Daniel Gallego & Juan Carlos Julián
1. Clinical care: Outcomes that matter to CKD patients
   Martin Wilkie, United Kingdom
2. Patient involvement in clinical studies
   Wanda Konijn & Hanneke Vervoort, The Netherlands
3. Involving patients in guideline development
   Tess Harris, United Kingdom

Symposium 4.3
CLINICAL ISSUES IN PERITONEAL DIALYSIS II
Chairs: Gianfranca Cabiddu & Angela Wang
1. Medical versus surgical intervention for advanced SHPT – which is better in dialysis patients?
   Angela Wang, Hong Kong
2. Incremental PD – Should this be the standard start in all incident PD Patients?
   Joanne Bargman, Canada
3. Promoting Exercise and physical activity in PD
   Monika Lichodziejewska-Niemierko, Poland

Symposium 5.2
RECIPIENT EVALUATION
Chairs: Rachel Hellemans & Umberto Maggiore
1. How to tackle the obesity pandemic in transplant candidates: the Descartes guideline
   Stephen O’Neill, United Kingdom
2. Retransplant candidates with failed graft: nephrectomy, management of immunosuppressants and other issues.
   Luuk Hibrands, The Netherlands
3. Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?
   Charles Ferro, United Kingdom
Free Communication 5
DR. HOUSE, COULD IT BE LUPUS?
Chairs: Gabriella Moroni & Manuel Praga
Mini Lecture: Sydney CW Tang, Hong Kong
Clinical and histological characteristics and long-term prognosis of late-onset lupus nephritis
Amir Shabaka, Spain
APOL1 genotype is a major determinant of lupus nephritis severity in patients of African ancestry
Carole Burge, France
Efficacy and safety of voclosporin in patients with proteinuria ≥2 mg/MG: an integrated analysis of the AURA-LV and Aurora 1 studies
Salem Almoani, United States of America
*b-cell recovery in a randomized controlled trial of b-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis (NOBILITY)
Dario Roccatoello, Italy

Free Communication 24
AKI ALCHEMY
Chairs: Gulay Demirtas & Francesco Trepiccione
Mini Lecture: Sho Hasegawa, Japan (JSN)
Activation of sympathetic signaling in macrophages blocks systemic inflammation and protects against renal ischemia-reperfusion injury
Recombinant high-density lipoprotein modulates inflammatory response and renal dysfunction in a swine model of sepsis-induced acute kidney injury
Alessandra Stasi, Italy
Short-chain fatty acids, propionate and butyrate, resemble the beneficial effects of vitamin D during acute kidney damage
Viviana Corte-Iglesias, Spain
CycL1 D1 ameliorates acutely injured kidney injury by improving fatty acid oxidation via AMPK pathway
Yuliang Huang, P.R. China
Microplastics: first extended proteomic analysis on kidney tubular cells
Carla Cervello, Italy

Free Communication 1
THE GOOD, THE BAD, AND THE CYSTIC
Chairs: Roman-Ulrich Müller & Carsten Wagner
Mini Lecture: Roser Torra
PKD: screening for cerebral aneurysms?
The autosomal recessive polycystic kidney disease protein, FPC, releases mitochondria localising fragments involved in preventing cystogenesis
Rebecca Walker, United Kingdom
Development of a new cellular model to evaluate the clinical impact of PKD1 variants exploiting CRISPR/Cas9 system
Martina Migliorero, Italy
Rapidly progressive autosomal dominant polycystic kidney disease: risk factors for disease severity during childhood and early adulthood.
Stijn Wigerinck, Belgium
Diagnostic yield of a targeted gene panel for monogenic kidney diseases: an European study
Silvia Giovanella, Italy

Free Communication 12
BLOODY STONES!
Chairs: Giovanni Gambaro & Markus Ketteler
Mini Lecture: Giovanni Gambaro, Italy
What’s new in urolithiasis European guidelines
Evaluation of haemoglobin response in patients with CKD-related anaemia not on dialysis receiving daprodustat or control in Ascend-ND
Vivekanand Jha, India
Profiles of hemoglobin trajectory in CKD patients and associated risks of major adverse cardiovascular events: the CKD-REIN cohort study
Lisa Le Gall, France
Effects of ferric citrate hydrate on fibroblast growth factor 23 and platelet count in CKD and non-CKD patients with iron deficiency anaemia
Kyoko Ito, Japan
Daprodustat versus recombinant human erythropoietin for treating anaemia of chronic kidney disease: cost effectiveness model methodology and findings
Alfred Sackeyfio, United Kingdom
PLENARY LECTURE 3 - YOUNG Awardees

**Chairs:** Ivan Rychlík & Alexander Rosenkranz

1. Basic Science  
   Christoph Kuppe, Germany

2. Translational Science  
   Stefanie Steiger, Germany  
   Edouard Fu, The Netherlands

3. Clinical Science  
   Olivier Aubert, France

**PLENARY LECTURE 3 - YOUNG Awardees**

**Symposium 0.5**  
**NEPHROLOGY PEARLS**  
**(CLOSING SESSION)**  

**Chairs:** Christoph Wanner & Francesca Mallamaci

1. Basic Science and Translational Nephrology  
   Nicole Endlich, Germany

2. Epidemiology and Clinical Nephrology  
   Manuel Ferrara, Italy

3. ESKD and Dialysis  
   Christian Combe, France

4. Kidney Transplantation  
   Rachel Hellemans, Belgium
# CONTENT & DAILY INDEX

## INDUSTRY SPONSORED SYMPOSIA

<table>
<thead>
<tr>
<th>Friday - June 16, 2023</th>
<th>Saturday - June 17, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>46</strong></td>
<td><strong>56</strong></td>
</tr>
</tbody>
</table>

## KDIGO 2023 CKD GUIDELINE: A BRAVE NEW WORLD ON THE EVALUATION, PROGNOSTICATION, AND MANAGEMENT OF KIDNEY DISEASE 49

## GENETIC SCREENING IN ADULT PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD) 49

## C3G AND IC-MPGN: FROM UNMET NEEDS TO A COLLABORATIVE APPROACH TOWARDS IMPROVING OUTCOMES 49

## IGA NEPHROPATHY: WHERE WE ARE NOW AND WHERE WE ARE GOING 49

## THE WINDOW OF OPPORTUNITY IN LUPUS NEPHRITIS: WHEN TO ACT TO IMPROVE KIDNEY OUTCOMES? 51

## FROM FIRST EVIDENCE TO FUTURE THERAPY: LEARNINGS FROM 2 DECADES OF FABRY EXPERIENCE 51

## POTASSIUM CONTROL ACROSS THE SPECTRUM OF CKD – OPTIMISING RAASI THERAPY AND IMPROVING PATIENT OUTCOMES 51

## BEYOND THE KIDNEY: NEW PERSPECTIVES IN INHERITED RARE DISEASES 53

## GLP-1 RAS: TOWARDS AN UNMET NEED OF PEOPLE WITH T2D AND CKD 53

## INSPIRED TO MOVE MOUNTAINS: EMERGING THERAPIES IN LUPUS NEPHRITIS 53

## ANCA-ASSOCIATED VASCULITIS, THE KIDNEY AND BEYOND 53

## ANEMIA OF CKD: TIME TO TAKE ACTION 54
**CONTENT & DAILY INDEX**

**FRIDAY - JUNE 16, 2023**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPLORE THE LATEST HOT TOPIC WITHIN IV IRON IN CKD AND HEART FAILURE</td>
<td>54</td>
</tr>
<tr>
<td>WHAT’S NEW IN THE MANAGEMENT OF ATYPICAL HEMOLYTIC URÆMIC SYNDROME?</td>
<td>54</td>
</tr>
<tr>
<td>ADSORPTION IN CHRONIC AND ACUTE CLINICAL SETTINGS</td>
<td>55</td>
</tr>
<tr>
<td>LUPUS NEPHRITIS: CURRENT CHALLENGES AND NOVEL TREATMENT STRATEGIES</td>
<td>55</td>
</tr>
</tbody>
</table>

**SATURDAY - JUNE 17, 2023**

<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPLORE THE LATEST HOT TOPIC WITHIN IV IRON IN CKD AND HEART FAILURE</td>
<td>54</td>
</tr>
<tr>
<td>WHAT’S NEW IN THE MANAGEMENT OF ATYPICAL HEMOLYTIC URÆMIC SYNDROME?</td>
<td>54</td>
</tr>
<tr>
<td>ADSORPTION IN CHRONIC AND ACUTE CLINICAL SETTINGS</td>
<td>55</td>
</tr>
<tr>
<td>LUPUS NEPHRITIS: CURRENT CHALLENGES AND NOVEL TREATMENT STRATEGIES</td>
<td>55</td>
</tr>
</tbody>
</table>
The Boehringer Ingelheim and Lilly Alliance is committed to helping people with Cardiovascular, Renal and Metabolic conditions.
16 FRI
INDUSTRY SPONSORED SYMPOSIA

ISS 1.1
KDIGO 2023 CKD GUIDELINE: A BRAVE NEW WORLD ON THE EVALUATION, PROGNOSTICATION, AND MANAGEMENT OF KIDNEY DISEASE
Chair: Adeera LEVIN, Canada
1. Welcome & introductions
   Adeera LEVIN, Canada
2. KDIGO 2023 CKD GL: Vision for the guideline: Why now?
   Paul STEVENS, United Kingdom
   Rumeysa KAZANGIOGLU, Turkey
4. KDIGO 2023 CKD GL: Delaying CKD Progression and Complications: What's new?
   Magdalena MADERO, Mexico
5. Q&A
   Adeera LEVIN, Canada

ISS 1.2
GENETIC SCREENING IN ADULT PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD)
Chair: Pietro Manuel FERRARO, Italy
1. Welcome and introductions
   Pietro Manuel FERRARO, Italy
2. Clinical utility of genetic testing in adults patients with CKD and ESKD
   Nine KNOERS, The Netherlands
3. Overcoming the challenges and barriers to genetic screening in routine clinical practice
   Carsten BERGMANN, Germany
4. How to successfully implement a screening programme for a rare genetic condition
   Pietro Manuel FERRARO, Italy
5. Panel discussion and summary
   All faculty

ISS 1.3
C3G AND IC-MPGN: FROM UNMET NEEDS TO A COLLABORATIVE APPROACH TOWARDS IMPROVING OUTCOMES
Chair: Fadi FAKHOURI, Switzerland
1. Welcome and introduction
   Fadi FAKHOURI, Switzerland
2. Current state of evidence in C3G and IC-MPGN and impact of uncertainties on clinical management
   Fadi FAKHOURI, Switzerland
3. The CompCure Association - on a mission to address evidence gaps
   Marianne SILKJAEER-NIELSEN, Switzerland
4. A comprehensive European Registry for C3G and IC-MPGN
   Franz SCHAEBER, Germany
5. Audience Q&A
   All faculty
6. Closing remarks
   Fadi FAKHOURI, Switzerland

ISS 1.4
IGA NEPHROPATHY: WHERE WE ARE NOW AND WHERE WE ARE GOING
Chair: Dana RIZK, United States of America
1. Complexity of IgAN management from a clinician perspective
   Rosanna COPPO, Italy
2. Review the emerging treatment landscape in IgAN
   Dana RIZK, United States of America

ORGANIZED BY
Boehringer Ingelheim
Lilly

ORGANIZED BY
Alnylam
Novartis
Reimagining Medicine
Did you know . . .

Blockade of the ETA receptor with potent and selective ETA antagonism represents a potential approach to treat IgAN patients at high risk of progression.
ISS 1.5
THE WINDOW OF OPPORTUNITY IN LUPUS NEPHRITIS: WHEN TO ACT TO IMPROVE KIDNEY OUTCOMES?
Chair: Liz LIGHTSTONE, United Kingdom
1. Welcome and Introduction
Liz LIGHTSTONE, United Kingdom
2. Case study 1: Forward thinking in the management of lupus nephritis
Lucio MANENTI, Italy
3. Case Study Discussion
Liz LIGHTSTONE, United Kingdom
4. Case study 2: Can we meet the challenge to improve kidney outcomes in lupus nephritis?
Y.K.Onno TENG, The Netherlands
5. Case study discussion
Liz LIGHTSTONE, United Kingdom
6. Closing Remarks
All faculty

ISS 1.6
FROM FIRST EVIDENCE TO FUTURE THERAPY: LEARNINGS FROM 2 DECADES OF FABRY EXPERIENCE
Chair: Antonio PISANI, Italy
1. Introduction
Antonio PISANI, Italy
2. More than 20 years of the patient-centered Fabry Registry: Real-world scientific evidence advancing Fabry disease expertise and better informing the Fabry community
Alberto ORTIZ, Spain
3. Cleared podocytes and normal kidney function in classical Fabry males 15 years after start of enzyme replacement therapy at young age
Camilla TØNDEL, Norway
4. Future oral therapies focusing on glucosylceramide synthase inhibition: evidence from clinical programs
Patrick DEEGAN, United Kingdom
5. Q & A
All faculty

ISS 1.7
POTASSIUM CONTROL ACROSS THE SPECTRUM OF CKD – OPTIMISING RAASI THERAPY AND IMPROVING PATIENT OUTCOMES
Chair: Francesca MALLAMACI, Italy
1. Hyperkalaemia – still an issue in the management of CKD?
Maria C. HALLER, Austria
2. Potassium control across the spectrum of CKD – practical guidance and novel therapeutic options
Patrick ROSSIGNOL, France
3. Optimising RAAS inhibition in patients with CKD and comorbidities – current guidelines and lessons from recent trials
Charles J. FERRO, United Kingdom
4. Interactive panel discussion
All faculty

ORGANIZED BY
GSK

ORGANIZED BY
sanofi

CSL Vifor
RAASi therapy is vital for patients with CKD and/or heart failure, but hyperkalemia can limit its use\textsuperscript{1-3}

Want to hear more? This KDIGO podcast features a discussion on the benefits of RAASi utilisation

LISTEN TODAY

KDIGO Conversations in Nephrology

LISTEN TO THE PODCAST

**INDUSTRY SPONSORED SYMPOSIA**

**ISS 1.8**
**BEYOND THE KIDNEY: NEW PERSPECTIVES IN INHERITED RARE DISEASES**

**Chair:** Christoph WANNER, Germany

1. Welcome and introduction
   Christoph WANNER, Germany

2. The importance of patients’ perspective for the assessment of symptoms. The unmet needs in FD from a patients’ perspective. Results of the patients’ survey
   Roser TORRA, Spain

3. The importance of patients’ perspective for the assessment of symptoms. Adults’ patients’ management in NC: clinical case reports
   Aude SERVAIS, France

4. How to update the optimal monitoring in FD considering the new data
   Antonio PISANI, Italy

5. Closing and remarks
   Christoph WANNER, Germany

**ISS 1.9**
**GLP-1 RAS: TOWARDS AN UNMET NEED OF PEOPLE WITH T2D AND CKD**

**Chair:** Peter ROSSING, Denmark

1. Welcome and Introduction
   Peter ROSSING, Denmark

2. What are we looking for in treatment of people with CKD and T2D?
   Adeera LEVIN, Canada

3. Clinical and treatment landscape of CKD and T2D.
   Roland E. SCHMIEDER, Germany

4. FLOW trial population: What FLOW GLP-1 RA kidney outcomes trial will add to current knowledge?
   Hiddo LAMBERS HEERSPINK, The Netherlands

**ISS 1.10**
**INSPIRED TO MOVE MOUNTAINS: EMERGING THERAPIES IN LUPUS NEPHRITIS**

**Chair:** Gabriella Luisa MORONI, Italy

1. Welcome and introduction
   Gabriella Luisa MORONI, Italy

2. Reaching base camp: B-cell depletion
   Rachel JONES, United Kingdom

3. One step at a time: complement inhibition
   Marina VIVARELLI, Italy

4. Climbing to the peak: from theory to clinical reality
   Liz LIGHTSTONE, United Kingdom

5. Q&A and close
   Gabriella Luisa MORONI, Italy

**ISS 1.11**
**ANCA-ASSOCIATED VASCULITIS, THE KIDNEY AND BEYOND**

**Chair:** Andreas KRONBICHLER, Austria

1. Welcome and introduction
   Andreas KRONBICHLER, Austria

2. Targeting unmet needs in clinical practice
   Federico ALBERICI, Italy

3. Ongoing challenges in ANCA-associated vasculitis—can we do better?
   Silke BRIX, United Kingdom

4. Q&A and Concluding Remarks
   Andreas KRONBICHLER, Austria

---

**ORGANIZED BY**

- CSL Vifor
- Roche
- Novo Nordisk
- Chiesi
**ISS 1.12**
**ANEMIA OF CKD: TIME TO TAKE ACTION**
Chair: Lucia DEL VECCHIO, Italy
1. Welcome and introduction
   Lucia DEL VECCHIO, Italy
2. Anemia of CKD: common, yet under-recognised?
   Ciro ESPOSITO, Italy
3. Patient-centred care to optimise current treatment
   Ciro ESPOSITO, Italy
   Frank STRUTZ, Germany
4. Latest innovations in patient care
   Frank STRUTZ, Germany
5. Summary and close
   Lucia DEL VECCHIO, Italy

**ISS 1.13**
**EXPLORE THE LATEST HOT TOPIC WITHIN IV IRON IN CKD AND HEART FAILURE**
Chair: Loreto GESUALDO, Italy
1. The value of an anemia management in a cardiorenal clinic
   Philip A. KALRA, United Kingdom
2. IRONMAN Trial Design – The emerging role of IV iron to reduce cardiovascular risk, particularly risk of hospitalisation for heart failure
   Fozia AHMED, United Kingdoms

---

**ISS 1.14**
**WHAT’S NEW IN THE MANAGEMENT OF ATYPICAL HEMOLYTIC URAEMIC SYNDROME?**
Chair: Manuel PRAGA, Spain
1. Overview of management approaches to aHUS
   Manuel PRAGA, Spain
2. Clinical and real-world experience with currently available targeted treatments for aHUS
   Anuja JAVA, United States of America
3. Recognition and management of aHUS in the presence of associated clinical conditions and events
   Sjoerd TIMMERMANS, The Netherlands
4. Q&A session
   All faculty
ISS 1.15
**ADSORPTION IN CHRONIC AND ACUTE CLINICAL SETTINGS**

**Chairs:** Claudio RONCO, Italy & Thomas Rimmelé, France

1. **Opening & Introduction**
   Claudio RONCO, Italy

2. **Improving Uremic Complications: How can Hemoadsorption Help**
   Dr. Vincenzo Cantaluppi, Italy

3. **Hemoadsorption in Septic Patients: Clinical Experience**
   Thomas RIMMELE, France

4. **DPMAS in ACLF: The PADSTONE study on 1300 Patients**
   Jinjun CHEN, China

5. **Discussion**
   All faculty

---

ISS 1.16
**LUPUS NEPHRITIS: CURRENT CHALLENGES AND NOVEL TREATMENT STRATEGIES**

**Chair:** Y.K. Onno TENG, The Netherlands

1. **Introduction**
   Y.K. Onno TENG, The Netherlands

2. **Current treatment: what are the unmet needs?**
   Andrea Doria, Italy

3. **New therapeutic options: is a paradigm change possible?**
   Gabriella Luisa MORONI, Italy

4. **Interactive survey and live Q&A**
   All faculty

---

**ORGANIZED BY**

Jafron

---

---
<table>
<thead>
<tr>
<th>Industry Sponsored Symposia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FRIDAY - JUNE 16, 2023</strong></td>
</tr>
<tr>
<td>46</td>
</tr>
<tr>
<td><strong>SATURDAY - JUNE 17, 2023</strong></td>
</tr>
<tr>
<td>56</td>
</tr>
</tbody>
</table>

| Challenges and Opportunities in IGA Nephropathy: Targeting the Alternative Complement Pathway | 58 |
| Strengthening Expertise in the Treatment of Chronic Kidney Disease | 58 |
| Continuing Lifesaving Therapy in the Cardiorenal Patient: Practical Guidance for Managing Hyperkalemia | 58 |
| Through Different Lenses: Understanding the Complexity of C3G and IC-MPGN | 58 |
| Filling the Gap by Targeting the Gut - First Disease Modifying Treatment Approved for IGA | 59 |
| Therapeutic Apheresis: Future Challenges | 59 |
| Patient-Centred Care in Dialysis: Let's Tackle CKD-Associated Pruritus | 59 |
| Achieving Success in IGA & FSGS: Expert Insights on Current and Future Therapies | 60 |
| Reshaping Kidney Care – Establishing the Full Potential of SGLT2 Inhibitors as Standard-of-Care | 60 |
| Immuno-Nephrology: The Dialysis Membrane as a Therapeutic Strategy | 60 |
| Hemocompatibility of Dialyzers – How Novel Membranes May Improve Hemodialysis Treatment | 60 |
| Nonsteroidal MRAs: A New Pillar of Treatment for Cardiorenal Protection in CKD and T2D | 62 |
| Complex Pathophysiology and Management in Anaemia of CKD: Is Roxadustat the Answer? | 62 |
| Ensuring a Treatment Continuum for CKD-MBD | 62 |
In Pursuit of Possibilities in IgA Nephropathy
INDUSTRY SPONSORED SYMPOSIA

ISS 2.1
CHALLENGES AND OPPORTUNITIES IN IGA NEPHROPATHY: TARGETING THE ALTERNATIVE COMPLEMENT PATHWAY

Chairs: Jürgen FLOEGE, Germany & Richard LAFAYETTE, United States of America
1. Welcome and introduction
   Richard LAFAYETTE, United States of America
2. The challenges with IgAN in clinical practice today
   Smeeta SINHA, United Kingdom
3. Complement in IgAN: A key driver of the pathogenesis?
   Sydney TANG, Hong Kong, P.R. China
4. Audience Q&A
   All faculty
5. Closing remarks
   All faculty

ISS 2.2
STRENGTHENING EXPERTISE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE

Chair: Jolanta MAŁYSZKO, Poland
1. Welcome & Introduction
   Jolanta MAŁYSZKO, Poland
2. Challenges and opportunities in the treatment in CKD
   David C. WHEELER, United Kingdom
3. Improving clinical outcomes in CKD: novel approaches
   Roberto PONTREMOLI, Italy
4. Commentary: Practical considerations for CKD management
   Rikke BORG, Denmark
5. Discussion & Closure
   Jolanta MAŁYSZKO, Poland

ORGANIZED BY

ISS 2.3
CONTINUING LIFESAVING THERAPY IN THE CARDIORENAL PATIENT: PRACTICAL GUIDANCE FOR MANAGING HYPERKALEMIA

Chair: James BURTON, United Kingdom
1. Welcome and introductions
   James BURTON, United Kingdom
2. Catch-22 – hyperkalemia and RAASi
   Manish SOOD, Canada
3. Reaching consensus – Optimising care for cardiorenal patients Panel Discussion
   Shelley ZIEROTH, Canada
4. Q&A
   All faculty

ORGANIZED BY

ISS 2.4
THROUGH DIFFERENT LENSES: UNDERSTANDING THE COMPLEXITY OF C3G AND IC-MPGN

Chair: Fernando CARAVACA-FONTÁN, Spain
1. Chair’s welcome
   Fernando CARAVACA-FONTÁN, Spain
2. Beneath the surface: the heterogeneous pathophysiology of C3G/IC-MPGN
   Marina NORIS, Italy
3. Demystifying the diagnostic pathway and disease progression in C3G/IC-MPGN
   Fernando CARAVACA-FONTÁN, Spain
4. The patient voice: the uncertainty of living with severe progressive kidney disease
   Antonia KING, Germany
5. Closing remarks and Q&A: Can we redefine the future of patient management in C3G/IC-MPGN
   Fernando CARAVACA-FONTÁN, Spain

ORGANIZED BY
INDUSTRY SPONSORED SYMPOSIA

ISS 2.5
FILLING THE GAP BY TARGETING THE GUT - FIRST DISEASE MODIFYING TREATMENT APPROVED FOR IGAN

Chair: Francesco Paolo SCHENA, Italy
1. Welcome and Introduction
   Francesco Paolo SCHENA, Italy
2. Nefecon – Rationale, Efficacy and Safety in the Treatment of Primary IgA Nephropathy
   Bengt FELLSTRÖM, Sweden
3. Nefigator and Beyond – Treating IgA Nephropathy in 2023
   Jonathan BARRATT, United Kingdom
4. Discussion & Closing Remarks
   Bengt FELLSTRÖM, Sweden, Jonathan BARRATT, United Kingdom

ISS 2.6
THERAPEUTIC APHERESIS: FUTURE CHALLENGES
Chair: Emanuela DE PASCALE, Italy
1. An apheresis centre – novel interdisciplinary treatment opportunities for nephrologists
   Benjamin SAVENKOFF, France
2. Lipoprotein apheresis - Quo vadis?
   Reinhard Georg KLINKE, Germany
3. Post-COVID-19 syndrome - is there a role for apheresis?
   Bernd HOHENSTEIN, Germany
4. Q&A
   All faculty

ISS 2.7
PATIENT-CENTRED CARE IN DIALYSIS: LET’S TACKLE CKD-ASSOCIATED PRURITUS
Chair: Lucio MANENTI, Italy
1. Welcome and introduction
   Lucio MANENTI, Italy
2. An insight into the burden and prevalence of CKD-associated Pruritus
   Antoine LANOT, France
3. An opportunity to improve CKD-associated Pruritus: Sharing clinical experience of difelikefalin
   Leonie KRAFT, Germany
4. An opportunity to improve CKD-associated Pruritus: Sharing clinical experience of difelikefalin
   Jörg LATUS, Germany
5. A changing landscape for the treatment of CKD-associated Pruritus
   Lucio MANENTI, Italy
6. Q&A
   All faculty
7. Summary and meeting close
   All faculty

ORGANIZED BY

AsahiKASEI

ORGANIZED BY

CSL Vifor
INDUSTRY SPONSORED SYMPOSIA

ISS 2.8
ACHIEVING SUCCESS IN IGA & FSGS: EXPERT INSIGHTS ON CURRENT AND FUTURE THERAPIES
Chair: Sian GRIFFIN, United Kingdom
1. Welcome
Sian GRIFFIN, United Kingdom
2. IgA Nephropathy Patient Case 1
Jürgen FLOEGE, Germany
3. IgA Nephropathy Patient Case 2
Loreto GESUALDO, Italy
4. IgAN Panel Discussion
All faculty
5. FSGS Patient Case
Sian GRIFFIN, United Kingdom
6. Panel Discussion, Take-Home Messages, and Question and Answer Session
All faculty

ISS 2.9
RESHAPING KIDNEY CARE – ESTABLISHING THE FULL POTENTIAL OF SGLT2 INHIBITORS AS STANDARD-OF-CARE
Chair: Kieran MCCAFFERTY, United Kingdom
1. Welcome and introductions
Kieran MCCAFFERTY, United Kingdom
2. From early to late in CKD – Nephrologists and their role before secondary care
Kieran MCCAFFERTY, United Kingdom
3. Time to make flozination as standard-of-care
David CHERNEY, Canada
4. Overcoming barriers to the use of SGLT2 inhibitors – Learnings from our journey so far
Paola FIORETTO, Italy
5. Panel discussion and Q&A
All faculty
6. Closing remarks
Kieran MCCAFFERTY, United Kingdom

ISS 2.10
IMMUNO-NEPHROLOGY: THE DIALYSIS MEMBRANE AS A THERAPEUTIC STRATEGY
Chairs: Ikuto MASAKANE, Japan & Giuseppe CASTELLANO, Italy
1. Waiting transplant patient and DGF: role of PMMA membrane
Giuseppe CASTELLANO, Italy
2. New frontier of anti-thrombogenic membrane: technology and clinical applications
Philippe RIEU, France
3. Inhibiting Complement Activation in Septic-AKI: Why Considering PMMA-based dialysis
Vincenzo CANTALUPPI, Italy
4. Final discussion
All faculty

ISS 2.11
HEMOCOMPATIBILITY OF DIALYZERS – HOW NOVEL MEMBRANES MAY IMPROVE HEMODIALYSIS TREATMENT
Chair: Alberto ORTIZ, Spain
1. Welcome and Introduction
Alberto ORTIZ, Spain
2. Inflammation – the fire that burns within
Peter STENVINKEL, Sweden
3. Biocompatibility of dialyzer membranes: relevance in current clinical practice
Muriel GROOTEMAN, The Netherlands
4. From bench to bedside – the new helixone hydro membrane
Fatih KIRCELLI, Germany
5. Q&A
All faculty

ORGANIZED BY
medtelligence®

ORGANIZED BY
‘TORAY’

ORGANIZED BY
FRESENIUS MEDICAL CARE
The symptoms of anaemia can be debilitating for our patients and effective management is key to improving quality of life and reducing the risk of adverse outcomes of anaemia in this challenging population.

This educational symposium will draw on the experience of the faculty to explore the clinical evidence, real-world experience, practicalities and potential of roxadustat, the first HIF-prolyl hydroxylase inhibitor to be approved for the treatment of adult patients with anaemia of CKD.

Chairperson: Professor Mario Cozzolino, University of Milan, Italy

Professor Denis Fouque, University Claude Bernard, Lyon, France

Professor Roberto Minutolo, University of Campania, Naples, Italy

Dr Monica Gross, DaVita Falkensee, Germany

The symptoms of anaemia can be debilitating for our patients and effective management is key to improving quality of life and reducing the risk of adverse outcomes of anaemia in this challenging population.

This educational symposium will draw on the experience of the faculty to explore the clinical evidence, real-world experience, practicalities and potential of roxadustat, the first HIF-prolyl hydroxylase inhibitor to be approved for the treatment of adult patients with anaemia of CKD.

“...”
INDUSTRY SPONSORED SYMPOSIA

ISS 2.12
NONSTEROIDAL MRAS: A NEW PILLAR OF TREATMENT FOR CARDIORENAL PROTECTION IN CKD AND T2D

Chair: Giuseppe GRANDALIANO, Italy
1. Welcome and introduction
   Giuseppe GRANDALIANO, Italy
2. Nonsteroidal MRAs as part of the comprehensive approach to CKD: Guideline updates
   Beatriz FERNANDEZ-FERNANDEZ, Spain
3. Pillar approach for the treatment of CKD in T2D: Treat early to help prevent further CV and renal damage
   Christoph WANNER, Germany
4. Beyond CKD progression: Cardiorenal protection across the spectrum of CKD in patients with T2D
   Rajiv AGARWAL, United States of America
5. Q&A
   All faculty
6. Summary and close
   Giuseppe GRANDALIANO, Italy

ISS 2.13
COMPLEX PATHOPHYSIOLOGY AND MANAGEMENT IN ANAEMIA OF CKD: IS ROXADUSTAT THE ANSWER?

Chair: Mario Gennaro COZZOLINO, Italy
1. Welcome and introduction
   Mario Gennaro COZZOLINO, Italy
2. The complexities of anaemia of CKD: disease burden, pathophysiology and management
   Denis FOUQUE, France
3. Roxadustat and the impact of a physiological approach to treatment
   Roberto MINUTOLO, Italy
4. Roxadustat in the real-world: the patient experience
   Monica, Gross, Germany
5. Q&A and meeting close
   Mario Gennaro COZZOLINO, Italy

ISS 2.14
ENSURING A TREATMENT CONTINUUM FOR CKD-MBD

Chair: Smeeta SINHA, United Kingdom
1. Welcome and introduction to vascular calcification
   Smeeta SINHA, United Kingdom
2. Importance of early and effective treatment of SHPT in non-dialysis CKD patients
   Jan T. KIELSTEIN, Germany
3. Decreasing pill burden in dialysis patients: advances in hyperphosphataemia treatment
   Maria Jesús LLORET, Spain
4. Key takeaways from the panel and close
   All faculty

ORGANIZED BY
CSL Vifor

astellas

ORGANIZED BY

BAYER
See you next year in Stockholm
Save the date
Vienna 2025